amiodarone has been researched along with Death, Sudden, Cardiac in 219 studies
Amiodarone: An antianginal and class III antiarrhythmic drug. It increases the duration of ventricular and atrial muscle action by inhibiting POTASSIUM CHANNELS and VOLTAGE-GATED SODIUM CHANNELS. There is a resulting decrease in heart rate and in vascular resistance.
amiodarone : A member of the class of 1-benzofurans that is 1-benzofuran substituted by a butyl group at position 2 and a 4-[2-(diethylamino)ethoxy]-3,5-diiodobenzoyl group at position 3. It is a cardiovascular drug used for the treatment of cardiac dysrhythmias.
Death, Sudden, Cardiac: Unexpected rapid natural death due to cardiovascular collapse within one hour of initial symptoms. It is usually caused by the worsening of existing heart diseases. The sudden onset of symptoms, such as CHEST PAIN and CARDIAC ARRHYTHMIAS, particularly VENTRICULAR TACHYCARDIA, can lead to the loss of consciousness and cardiac arrest followed by biological death. (from Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine, 7th ed., 2005)
| Excerpt | Relevance | Reference |
|---|---|---|
| "In the SCD-HeFT (Sudden Cardiac Death in Heart Failure Trial), a pre-specified subgroup analysis showed that patients with New York Heart Association functional class III symptoms did not benefit from implantable cardioverter-defibrillator (ICD) therapy and appeared to be harmed by amiodarone, whereas New York Heart Association functional class II patients obtained significant survival benefit from ICD." | 9.19 | Use of the 6-min walk distance to identify variations in treatment benefits from implantable cardioverter-defibrillator and amiodarone: results from the SCD-HeFT (Sudden Cardiac Death in Heart Failure Trial). ( Anderson, J; Bardy, GH; Fishbein, DP; Hellkamp, AS; Johnson, G; Lee, KL; Mark, DB; Poole, JE; Walsh, MN, 2014) |
| "Amiodarone's efficacy in maintaining sinus rhythm and reducing the burden of atrial fibrillation is similar in the presence or absence of severe left ventricular dysfunction." | 9.19 | Efficacy of amiodarone in patients with atrial fibrillation with and without left ventricular dysfunction: a pooled analysis of AFFIRM and AF-CHF trials. ( Andrade, JG; Blondeau, L; Cadrin-Tourigny, J; Dubuc, M; Guerra, PG; Khairy, P; Levesque, S; Macle, L; Rivard, L; Roy, D; Talajic, M; Thibault, B; Wyse, DG, 2014) |
| "Uncertainty persists about the safety and efficacy of amiodarone for the management of heart failure." | 9.12 | The safety of amiodarone in patients with heart failure. ( Cleland, JG; Di Lenarda, A; Komajda, M; Lukas, MA; Metra, M; Moullet, C; Poole-Wilson, PA; Remme, W; Scherhag, A; Spark, P; Swedberg, K; Torp-Pedersen, C, 2007) |
| "We sought to compare the long-term survival rates of patients with sustained ventricular tachyarrhythmia after myocardial infarction (MI) who were treated according to the results of electrophysiological (EP) study either with amiodarone or an implantable cardioverter-defibrillator (ICD)." | 9.10 | Electrophysiologically guided amiodarone therapy versus the implantable cardioverter-defibrillator for sustained ventricular tachyarrhythmias after myocardial infarction: results of long-term follow-up. ( Fromer, M; Kappenberger, L; Rapp, F; Schläpfer, J, 2002) |
| "Although amiodarone was effective in suppressing ventricular arrhythmias and improving ventricular function, it did not reduce the incidence of sudden death or prolong survival among patients with heart failure, except for a trend toward reduced mortality among those with nonischemic cardiomyopathy." | 9.08 | Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure. ( Colling, C; Deedwania, PC; Fisher, SG; Fletcher, RD; Lazzeri, D; Lewis, HD; Massie, BM; Singh, BN; Singh, SN, 1995) |
| "The European Myocardial Infarct Amiodarone Trial (EMIAT) was a randomised double-blind placebo-controlled trial to assess whether amiodarone reduced all-cause mortality (primary endpoint) and cardiac mortality and arrhythmic death (secondary endpoints) in survivors of myocardial infarction with a left-ventricular ejection fraction (LVEF) of 40% or less." | 9.08 | Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT. European Myocardial Infarct Amiodarone Trial Investigators. ( Camm, AJ; Frangin, G; Janse, MJ; Julian, DG; Munoz, A; Schwartz, PJ; Simon, P, 1997) |
| "Amiodarone reduces the incidence of ventricular fibrillation or arrhythmic death among survivors of acute myocardial infarction with frequent or repetitive VPDs." | 9.08 | Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT. Canadian Amiodarone Myocardial Infarction Arrhythmia Trial Investigators. ( Cairns, JA; Connolly, SJ; Gent, M; Roberts, R, 1997) |
| "The impact of amiodarone on mortality in patients with severe congestive heart failure (CHF) (New York Heart Association functional classes II [advanced], III and IV; left ventricular ejection fraction < 35%) In the Grupo de Estudio de la Sobrevida en la Insuficiencia Cardiaca en Argentina (GESICA) trial was analyzed in relation to initial mean baseline heart rate (BHR) and its change after 6 months of follow-up." | 9.08 | Heart rate is a marker of amiodarone mortality reduction in severe heart failure. The GESICA-GEMA Investigators. Grupo de Estudio de la Sobrevida en la Insuficiencia Cardiaca en Argentina-Grupo de Estudios Multicéntricos en Argentina. ( Doval, HC; Grancelli, HO; Nul, DR; Perrone, SV; Prieto, N; Scapin, O; Soifer, S; Varini, SD, 1997) |
| "A randomized trial was conducted to assess the efficacy of amiodarone versus metoprolol or no antiarrhythmic treatment to suppress asymptomatic ectopic activity and improve survival in patients who have had myocardial infarction with a left ventricular ejection fraction of 20 to 45% and > or = 3 ventricular premature complexes per hour (pairs or runs)." | 9.07 | Comparison of the effects of amiodarone versus metoprolol on the frequency of ventricular arrhythmias and on mortality after acute myocardial infarction. SSSD Investigators. Spanish Study on Sudden Death. ( Bayes de Luna, A; Cosin, J; Guindo, J; Marrugat, J; Navarro-López, F, 1993) |
| "In the Basel Antiarrhythmic Study of Infarct Survival trial, low-dose amiodarone improved 1-year survival in patients with asymptomatic complex ventricular arrhythmias persisting 2 weeks after myocardial infarction." | 9.07 | Long-term benefit of 1-year amiodarone treatment for persistent complex ventricular arrhythmias after myocardial infarction. ( Brunner, H; Burckhardt, D; Burkart, F; Kiowski, W; Pfisterer, ME, 1993) |
| "In the BASIS study, an improvement in 1 year survival of patients with asymptomatic complex ventricular arrhythmias with low-dose amiodarone was shown in comparison with an untreated control group." | 9.07 | [Long-term effect of amiodarone therapy following myocardial infarct in patients with complex ventricular arrhythmias]. ( Brunner, H; Burckhardt, D; Burkart, F; Kiowski, W; Pfisterer, M, 1993) |
| "There have been 13 randomised controlled trials of prophylactic amiodarone in patients with recent myocardial infarction (MI) or congestive heart failure (CHF)." | 8.79 | Effect of prophylactic amiodarone on mortality after acute myocardial infarction and in congestive heart failure: meta-analysis of individual data from 6500 patients in randomised trials. Amiodarone Trials Meta-Analysis Investigators. ( , 1997) |
| "The prophylactic administration of amiodarone following acute myocardial infarction has been investigated in several small trials." | 8.78 | Empiric long-term amiodarone prophylaxis following myocardial infarction. A meta-analysis. ( Caruso, AC; Nolan, PE; Slack, MK; Zarembski, DG, 1993) |
| "To determine the efficacy necessary to make prophylactic ICD or amiodarone therapy cost-effective in patients with myocardial infarction." | 7.71 | Potential cost-effectiveness of prophylactic use of the implantable cardioverter defibrillator or amiodarone after myocardial infarction. ( Every, NR; Heidenreich, PA; Hlatky, MA; McDonald, KM; Owens, DK; Parsons, LS; Sanders, GD, 2001) |
| "The medical records, including radiographic imaging, pathology and operative reports, of 2 postpubertal boys who had sterile epididymitis after prolonged therapy with amiodarone were reviewed." | 7.70 | Amiodarone induced epididymitis in children. ( Diamond, DA; Hutcheson, J; Peters, CA, 1998) |
| "We compared the ability of a new amiodarone-like agent, SR 33589, with that of amiodarone, D,L-sotalol, and lignocaine to reduce the incidence of ventricular fibrillation (VF) and associated arrhythmias caused by acute coronary artery occlusion in anesthetized pigs." | 7.69 | Effects of a new amiodarone-like agent, SR 33589, in comparison to amiodarone, D,L-sotalol, and lignocaine, on ischemia-induced ventricular arrhythmias in anesthetized pigs. ( Chatelain, P; Finance, O; Manning, A, 1995) |
| "To examine the value of programmed electrical stimulation of the heart in predicting sudden death in patients receiving amiodarone to treat ventricular tachyarrhythmias after myocardial infarction." | 7.69 | Induction of ventricular fibrillation predicts sudden death in patients treated with amiodarone because of ventricular tachyarrhythmias after a myocardial infarction. ( den Dulk, K; Oreto, G; Rodríguez, LM; Smeets, JL; Sternick, EB; Timmermans, C; Wellens, HJ, 1996) |
| "One hundred twenty-two patients treated chronically with amiodarone for sustained ventricular tachycardia or ventricular fibrillation after failing conventional antiarrhythmic therapy were analyzed to determine which factors were predictive of sudden cardiac death during follow-up." | 7.68 | Stratification of sudden death risk in patients receiving long-term amiodarone treatment for sustained ventricular tachycardia or ventricular fibrillation. ( Foster, JR; Olson, PJ; Simpson, RJ; Woelfel, A, 1993) |
| "A group of 34 consecutive patients with coronary artery disease (n = 29) or dilated cardiomyopathy (n = 5) (3 women, 31 men, age 38-80 yr) who had severely impaired left ventricular function (left ventricular ejection fraction less than or equal to 40%) and high-grade ventricular ectopic activity (sustained or nonsustained ventricular tachycardia or ventricular fibrillation) were treated with amiodarone (mean dose: 206 mg/d) and followed for 1-117 (mean: 49) months." | 7.68 | Long-term treatment of ventricular tachycardia with amiodarone in presence of severe left ventricular dysfunction. ( Burckhardt, D; Hoffmann, A; Pfisterer, M; Robertson, A, 1991) |
| "Intravenous amiodarone was administered to 22 patients with recurrent ventricular tachycardia failing an average of 3." | 7.68 | Intravenous amiodarone for short-term treatment of refractory ventricular tachycardia or fibrillation. ( DonMichael, TA; Ismail, Y; Nalos, PC; Nyitray, W; Pappas, JM, 1991) |
| "Amiodarone is a Class III Vaughan-Williams anti-arrhythmic drug widely used in ventricular arrhythmias for its efficacy and low pro-arrhythmogenic effect." | 6.72 | Amiodarone in ventricular arrhythmias: still a valuable resource? ( Baldetti, L; Brugliera, L; Cianfanelli, L; D'Angelo, G; De Blasi, G; Della Bella, P; Falasconi, G; Frontera, A; Gulletta, S; Landoni, G; Malatino, L; Margonato, A; Melillo, F; Ossola, P; Pannone, L; Vergara, P; Zacchetti, D, 2021) |
| "Treatment with amiodarone or an implantable cardioverter-defibrillator (ICD) has been proposed to improve the prognosis in such patients." | 6.71 | Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. ( Anderson, J; Bardy, GH; Boineau, R; Clapp-Channing, N; Davidson-Ray, LD; Domanski, M; Fishbein, DP; Fraulo, ES; Ip, JH; Johnson, G; Lee, KL; Luceri, RM; Mark, DB; McNulty, SE; Packer, DL; Poole, JE; Troutman, C, 2005) |
| "Amiodarone was administered at a dosage of 800 mg/day for 2 weeks followed by 400 mg/day thereafter." | 6.68 | Effect of amiodarone therapy on mortality in patients with left ventricular dysfunction and asymptomatic complex ventricular arrhythmias: Argentine Pilot Study of Sudden Death and Amiodarone (EPAMSA). ( Gambarte, A; Garguichevich, JJ; Gentile, A; Hauad, S; Ramos, JL; Scapin, O; Sirena, J; Tibaldi, M; Toplikar, J, 1995) |
| "A similar morning peak of sudden cardiac death was found in both the amiodarone (n = 42) and the placebo (n = 54) groups, and the overall circadian pattern did not differ between them (p = 0." | 6.68 | Effects of amiodarone on the circadian pattern of sudden cardiac death (Department of Veterans Affairs Congestive Heart Failure-Survival Trial of Antiarrhythmic Therapy). ( Behrens, S; Fisher, SG; Fletcher, RD; Franz, MR; Ney, G; Singh, SN, 1997) |
| "Sudden cardiac death is a common cause of mortality in patients with congestive heart failure." | 6.67 | Prospective, double-blind, placebo-controlled trial of low-dose amiodarone in patients with severe heart failure and asymptomatic frequent ventricular ectopy. ( Das, SK; Krikler, SJ; McKenna, WJ; Mickelson, JK; Morady, F; Nicklas, JM; Pitt, B; Quain, LA; Schork, MA; Stewart, RA, 1991) |
| "Further studies, including the Sudden Cardiac Death Heart Trial (SCD HeFT), should help determine the role of amiodarone in heart failure patients." | 6.40 | Amiodarone in congestive heart failure. ( Singh, S, 1998) |
| "No sustained ventricular tachycardia, ventricular fibrillation, sudden cardiac death, or cardiovascular mortality were observed." | 5.72 | Propafenone use in coronary artery disease patients undergoing atrial fibrillation ablation. ( Aksu, T; Aras, D; Cay, S; Kara, M; Ozcan, F; Ozeke, O; Topaloglu, S, 2022) |
| "The SCD-HeFT (Sudden Cardiac Death in Heart Failure Trial) randomized 2,521 patients with moderate heart failure (HF) to amiodarone, placebo drug, or implantable cardioverter-defibrillator (ICD) therapy." | 5.34 | Long-Term Outcomes of Implantable Cardioverter-Defibrillator Therapy in the SCD-HeFT. ( Anderson, J; Anstrom, KJ; Bardy, GH; Boineau, RE; Davidson-Ray, L; Fishbein, DP; Hellkamp, AS; Johnson, G; Lee, KL; Mark, DB; Olshansky, B; Packer, DL; Poole, JE; Reinhall, PG, 2020) |
| "In the SCD-HeFT (Sudden Cardiac Death in Heart Failure Trial), a pre-specified subgroup analysis showed that patients with New York Heart Association functional class III symptoms did not benefit from implantable cardioverter-defibrillator (ICD) therapy and appeared to be harmed by amiodarone, whereas New York Heart Association functional class II patients obtained significant survival benefit from ICD." | 5.19 | Use of the 6-min walk distance to identify variations in treatment benefits from implantable cardioverter-defibrillator and amiodarone: results from the SCD-HeFT (Sudden Cardiac Death in Heart Failure Trial). ( Anderson, J; Bardy, GH; Fishbein, DP; Hellkamp, AS; Johnson, G; Lee, KL; Mark, DB; Poole, JE; Walsh, MN, 2014) |
| "Amiodarone's efficacy in maintaining sinus rhythm and reducing the burden of atrial fibrillation is similar in the presence or absence of severe left ventricular dysfunction." | 5.19 | Efficacy of amiodarone in patients with atrial fibrillation with and without left ventricular dysfunction: a pooled analysis of AFFIRM and AF-CHF trials. ( Andrade, JG; Blondeau, L; Cadrin-Tourigny, J; Dubuc, M; Guerra, PG; Khairy, P; Levesque, S; Macle, L; Rivard, L; Roy, D; Talajic, M; Thibault, B; Wyse, DG, 2014) |
| "The Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) demonstrated that implantable cardioverter defibrillator (ICD) therapy reduced overall mortality in patients with class II or III heart failure and left ventricular ejection fraction (LVEF) | 5.13 | Primary prevention with defibrillator therapy in women: results from the Sudden Cardiac Death in Heart Failure Trial. ( Anderson, J; Bardy, GH; Domanski, M; Hellkamp, AS; Johnson, GW; Lee, KL; Mark, DB; Poole, JE; Russo, AM, 2008) |
| "Uncertainty persists about the safety and efficacy of amiodarone for the management of heart failure." | 5.12 | The safety of amiodarone in patients with heart failure. ( Cleland, JG; Di Lenarda, A; Komajda, M; Lukas, MA; Metra, M; Moullet, C; Poole-Wilson, PA; Remme, W; Scherhag, A; Spark, P; Swedberg, K; Torp-Pedersen, C, 2007) |
| "We sought to compare the long-term survival rates of patients with sustained ventricular tachyarrhythmia after myocardial infarction (MI) who were treated according to the results of electrophysiological (EP) study either with amiodarone or an implantable cardioverter-defibrillator (ICD)." | 5.10 | Electrophysiologically guided amiodarone therapy versus the implantable cardioverter-defibrillator for sustained ventricular tachyarrhythmias after myocardial infarction: results of long-term follow-up. ( Fromer, M; Kappenberger, L; Rapp, F; Schläpfer, J, 2002) |
| "Although amiodarone was effective in suppressing ventricular arrhythmias and improving ventricular function, it did not reduce the incidence of sudden death or prolong survival among patients with heart failure, except for a trend toward reduced mortality among those with nonischemic cardiomyopathy." | 5.08 | Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure. ( Colling, C; Deedwania, PC; Fisher, SG; Fletcher, RD; Lazzeri, D; Lewis, HD; Massie, BM; Singh, BN; Singh, SN, 1995) |
| "The European Myocardial Infarct Amiodarone Trial (EMIAT) was a randomised double-blind placebo-controlled trial to assess whether amiodarone reduced all-cause mortality (primary endpoint) and cardiac mortality and arrhythmic death (secondary endpoints) in survivors of myocardial infarction with a left-ventricular ejection fraction (LVEF) of 40% or less." | 5.08 | Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT. European Myocardial Infarct Amiodarone Trial Investigators. ( Camm, AJ; Frangin, G; Janse, MJ; Julian, DG; Munoz, A; Schwartz, PJ; Simon, P, 1997) |
| "Amiodarone reduces the incidence of ventricular fibrillation or arrhythmic death among survivors of acute myocardial infarction with frequent or repetitive VPDs." | 5.08 | Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT. Canadian Amiodarone Myocardial Infarction Arrhythmia Trial Investigators. ( Cairns, JA; Connolly, SJ; Gent, M; Roberts, R, 1997) |
| "The impact of amiodarone on mortality in patients with severe congestive heart failure (CHF) (New York Heart Association functional classes II [advanced], III and IV; left ventricular ejection fraction < 35%) In the Grupo de Estudio de la Sobrevida en la Insuficiencia Cardiaca en Argentina (GESICA) trial was analyzed in relation to initial mean baseline heart rate (BHR) and its change after 6 months of follow-up." | 5.08 | Heart rate is a marker of amiodarone mortality reduction in severe heart failure. The GESICA-GEMA Investigators. Grupo de Estudio de la Sobrevida en la Insuficiencia Cardiaca en Argentina-Grupo de Estudios Multicéntricos en Argentina. ( Doval, HC; Grancelli, HO; Nul, DR; Perrone, SV; Prieto, N; Scapin, O; Soifer, S; Varini, SD, 1997) |
| "A randomized trial was conducted to assess the efficacy of amiodarone versus metoprolol or no antiarrhythmic treatment to suppress asymptomatic ectopic activity and improve survival in patients who have had myocardial infarction with a left ventricular ejection fraction of 20 to 45% and > or = 3 ventricular premature complexes per hour (pairs or runs)." | 5.07 | Comparison of the effects of amiodarone versus metoprolol on the frequency of ventricular arrhythmias and on mortality after acute myocardial infarction. SSSD Investigators. Spanish Study on Sudden Death. ( Bayes de Luna, A; Cosin, J; Guindo, J; Marrugat, J; Navarro-López, F, 1993) |
| " In 1987, the Cardiac Arrest Study Hamburg (CASH), a prospective, randomized trial, was initiated to compare metoprolol, amiodarone, propafenone, and ICD implantation in patients surviving sudden cardiac death due to documented ventricular tachycardia and/or ventricular fibrillation." | 5.07 | Preliminary results of the Cardiac Arrest Study Hamburg (CASH). CASH Investigators. ( Cappato, R; Kuck, KH; Rüppel, R; Schneider, MA; Siebels, J, 1993) |
| "In the Basel Antiarrhythmic Study of Infarct Survival trial, low-dose amiodarone improved 1-year survival in patients with asymptomatic complex ventricular arrhythmias persisting 2 weeks after myocardial infarction." | 5.07 | Long-term benefit of 1-year amiodarone treatment for persistent complex ventricular arrhythmias after myocardial infarction. ( Brunner, H; Burckhardt, D; Burkart, F; Kiowski, W; Pfisterer, ME, 1993) |
| "In the BASIS study, an improvement in 1 year survival of patients with asymptomatic complex ventricular arrhythmias with low-dose amiodarone was shown in comparison with an untreated control group." | 5.07 | [Long-term effect of amiodarone therapy following myocardial infarct in patients with complex ventricular arrhythmias]. ( Brunner, H; Burckhardt, D; Burkart, F; Kiowski, W; Pfisterer, M, 1993) |
| "The EMIAT is a randomized, double-blind trial versus placebo, designed to evaluate the efficacy of amiodarone in the prevention of total mortality in patients with left ventricular ejection fraction of under 40% after myocardial infarction." | 5.07 | [Amiodarone and secondary prevention. The EMIAT study]. ( Munoz, A, 1991) |
| "Amiodarone is the most widely used antiarrhythmic agent, with demonstrated effectiveness against all the spectrum of cardiac tachyarrhythmias." | 4.88 | Examining the safety of amiodarone. ( Bai, R; Burkhardt, JD; Di Biase, L; Mohanty, P; Natale, A; Pump, A; Santangeli, P, 2012) |
| " More efforts are needed to improve the success rate of out-of-hospital resuscitation through better warning systems, the use of amiodarone for refractory arrhythmias, and the widespread availability of automated defibrillation devices to allow early defibrillation." | 4.82 | Sudden cardiac death: prevention and treatment. ( Kwok, KM; Lau, CP; Lee, KL; Tse, HF, 2003) |
| " For patients who have a history of sustained ventricular tachycardia(VT) or ventricular fibrillation(VF) amiodarone or an implantable cardioverter defibrillator(ICD) should be considered, and these therapy may benefit some high risk patients who have nonsustained VT." | 4.81 | [Heart failure]. ( Komuro, I; Yonezawa, M, 2002) |
| "n 1987 the results of the Consensus study were published, and showed that enalapril, an angiotensin convertor enzyme inhibitor (ACEI), was able to modify the clinical course of the heart failure syndrome thereby reducing mortality." | 4.81 | [Clinical trials on heart failure]. ( Cosín Aguilar, J; Hernándiz Martínez, A, 2001) |
| "Despite the antiarrhythmic efficacy of amiodarone, a definitive correlation between amiodarone treatment and increased non-arrhythmic mortality in patients with heart failure and depressed ventricular function has been reported." | 4.80 | Perspectives: does amiodarone increase non-sudden deaths? If so, why? ( Auricchio, A; Klein, HU; Nisam, S, 2000) |
| " The trials were conducted independently from each other and both have a randomized, placebo controlled design to assess the efficacy of the class III agent amiodarone in patients with acute myocardial infarction." | 4.79 | [Anti-arrhythmia therapy after myocardial infarct: preliminary results of EMIAT and CAMIAT studies]. ( Kuck, KH, 1996) |
| "There have been 13 randomised controlled trials of prophylactic amiodarone in patients with recent myocardial infarction (MI) or congestive heart failure (CHF)." | 4.79 | Effect of prophylactic amiodarone on mortality after acute myocardial infarction and in congestive heart failure: meta-analysis of individual data from 6500 patients in randomised trials. Amiodarone Trials Meta-Analysis Investigators. ( , 1997) |
| "The prophylactic administration of amiodarone following acute myocardial infarction has been investigated in several small trials." | 4.78 | Empiric long-term amiodarone prophylaxis following myocardial infarction. A meta-analysis. ( Caruso, AC; Nolan, PE; Slack, MK; Zarembski, DG, 1993) |
| "Amiodarone, an anti-ischaemic and anti-arrhythmic drug, has been the object of numerous studies and seems to be highly effective in the treatment of severe ventricular arrhythmias on dilated cardiomyopathies, as well as of hypertrophic or ischaemic heart diseases." | 4.78 | [Does amiodarone have a benefit effect on mortality?]. ( Kahn, JC; Pathé, M, 1991) |
| " In the ICD group, adequate interventions appear mainly in the initial observation period (HR 2,01), in patients with left ventricular hypertrophy (HR 2,98) and ventricular arrhythmias (HR 6,78) and not treated with amiodarone (HR 4,31)." | 3.85 | [Predictive parameters of occurrence of adequate interventions in patients with implanted cardioverter-defibrillators with or without resynchronisation therapy in primary prevention of sudden cardiac death in dilated cardiomyopathy]. ( Lelakowska, M; Lelakowski, J; Piekarz, J; Pudło, J; Rydlewska, A, 2017) |
| "2%) corresponding to patients in AVID where the risk was moderate and ICD/PM and amiodarone had equal efficacy, demonstrated a two-fold higher risk of sudden arrhythmic than non-arrhythmic death and hence would be expected to benefit from antiarrhythmia therapy." | 3.74 | Clinical criteria for predicting benefit of ICD/PM in post myocardial infarction patients: an AVID and CAST analysis. ( Hallstrom, AP; McAnulty, J; Wyse, DG, 2008) |
| " In the case of amiodarone, clinical trial data to date suggest that it should not be used for primary prevention of SCD or to prolong survival in patients with congestive heart failure secondary to coronary artery disease." | 3.72 | A guide to device selection: cardiac resynchronization therapy alone or in combination with an implantable cardioverter defibrillator. ( Prystowsky, EN, 2003) |
| "Baroreflex sensitivity was assessed in 287 patients with history of myocardial infarction and left ventricular ejection fraction < or =40% by phenylephrine test and was found to be depressed (4." | 3.72 | [Correction of baroreflex sensitivity impairment and efficacy of prevention of sudden arrhythmic death in patients with postinfarction left ventricular dysfunction]. ( Bozhko, AA; Kanopskiĭ, SG; Staritskiĭ, AG, 2004) |
| "To determine the efficacy necessary to make prophylactic ICD or amiodarone therapy cost-effective in patients with myocardial infarction." | 3.71 | Potential cost-effectiveness of prophylactic use of the implantable cardioverter defibrillator or amiodarone after myocardial infarction. ( Every, NR; Heidenreich, PA; Hlatky, MA; McDonald, KM; Owens, DK; Parsons, LS; Sanders, GD, 2001) |
| "The medical records, including radiographic imaging, pathology and operative reports, of 2 postpubertal boys who had sterile epididymitis after prolonged therapy with amiodarone were reviewed." | 3.70 | Amiodarone induced epididymitis in children. ( Diamond, DA; Hutcheson, J; Peters, CA, 1998) |
| "The aim of this study was to evaluate the survival of patients with hypertrophic cardiomyopathy (HCM) after resuscitated ventricular fibrillation or syncopal sustained ventricular tachycardia (VT/VF) when treated with low dose amiodarone or implantable cardioverter defibrillators (ICDs)." | 3.70 | Survival after cardiac arrest or sustained ventricular tachycardia in patients with hypertrophic cardiomyopathy. ( Elliott, PM; McKenna, WJ; Poloniecki, J; Rowland, E; Sharma, S; Varnava, A, 1999) |
| "We compared the ability of a new amiodarone-like agent, SR 33589, with that of amiodarone, D,L-sotalol, and lignocaine to reduce the incidence of ventricular fibrillation (VF) and associated arrhythmias caused by acute coronary artery occlusion in anesthetized pigs." | 3.69 | Effects of a new amiodarone-like agent, SR 33589, in comparison to amiodarone, D,L-sotalol, and lignocaine, on ischemia-induced ventricular arrhythmias in anesthetized pigs. ( Chatelain, P; Finance, O; Manning, A, 1995) |
| "To examine the value of programmed electrical stimulation of the heart in predicting sudden death in patients receiving amiodarone to treat ventricular tachyarrhythmias after myocardial infarction." | 3.69 | Induction of ventricular fibrillation predicts sudden death in patients treated with amiodarone because of ventricular tachyarrhythmias after a myocardial infarction. ( den Dulk, K; Oreto, G; Rodríguez, LM; Smeets, JL; Sternick, EB; Timmermans, C; Wellens, HJ, 1996) |
| "One hundred twenty-two patients treated chronically with amiodarone for sustained ventricular tachycardia or ventricular fibrillation after failing conventional antiarrhythmic therapy were analyzed to determine which factors were predictive of sudden cardiac death during follow-up." | 3.68 | Stratification of sudden death risk in patients receiving long-term amiodarone treatment for sustained ventricular tachycardia or ventricular fibrillation. ( Foster, JR; Olson, PJ; Simpson, RJ; Woelfel, A, 1993) |
| "A group of 34 consecutive patients with coronary artery disease (n = 29) or dilated cardiomyopathy (n = 5) (3 women, 31 men, age 38-80 yr) who had severely impaired left ventricular function (left ventricular ejection fraction less than or equal to 40%) and high-grade ventricular ectopic activity (sustained or nonsustained ventricular tachycardia or ventricular fibrillation) were treated with amiodarone (mean dose: 206 mg/d) and followed for 1-117 (mean: 49) months." | 3.68 | Long-term treatment of ventricular tachycardia with amiodarone in presence of severe left ventricular dysfunction. ( Burckhardt, D; Hoffmann, A; Pfisterer, M; Robertson, A, 1991) |
| "Intravenous amiodarone was administered to 22 patients with recurrent ventricular tachycardia failing an average of 3." | 3.68 | Intravenous amiodarone for short-term treatment of refractory ventricular tachycardia or fibrillation. ( DonMichael, TA; Ismail, Y; Nalos, PC; Nyitray, W; Pappas, JM, 1991) |
| "ICD therapy did not reduce the risk of sudden cardiac death in HFrEF patients with diabetes (HR = 0." | 2.90 | Efficacy of an implantable cardioverter-defibrillator in patients with diabetes and heart failure and reduced ejection fraction. ( Dewan, P; Jhund, PS; Kristensen, SL; Køber, L; McMurray, JJV; Petrie, MC; Rørth, R, 2019) |
| "In the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT), a significant fraction of the patients with congestive heart failure ultimately did not die suddenly of arrhythmic causes." | 2.80 | SCD-HeFT: Use of R-R interval statistics for long-term risk stratification for arrhythmic sudden cardiac death. ( Anderson, J; Au-Yeung, WT; Bardy, GH; Fletcher, RD; Johnson, G; Lee, KL; Mark, DB; Moore, HJ; Poole, JE; Reinhall, PG, 2015) |
| "In the SCD-HeFT (Sudden Cardiac Death in Heart Failure Trial), the type of imaging modality for EF assessment was not mandated." | 2.73 | Ejection fraction assessment and survival: an analysis of the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). ( Anderson, J; Bardy, GH; Gula, LJ; Hellkamp, AS; Johnson, GW; Klein, GJ; Krahn, AD; Lee, KL; Mark, DB; Massel, D; Poole, JE; Skanes, AC; Yee, R, 2008) |
| "Amiodarone's role as a cause of toxic optic neuropathy is based on case reports." | 2.73 | Absence of bilateral vision loss from amiodarone: a randomized trial. ( Anderson, J; Bardy, GH; Hellkamp, A; Johnson, G; Lee, KL; Mark, DB; Mindel, JS; Poole, JE, 2007) |
| "In the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT), 2521 patients with moderate heart failure were randomized to receive amiodarone, implanted cardioverter-defibrillators (ICDs), or placebo." | 2.73 | Risk of thromboembolism in heart failure: an analysis from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). ( Anderson, J; Bardy, GH; Freudenberger, RS; Halperin, JL; Hellkamp, AS; Johnson, G; Lee, KL; Mark, DB; Poole, J, 2007) |
| "Syncope was associated with increased mortality risk in SCD-HeFT regardless of treatment arm (placebo, amiodarone, or ICD)." | 2.73 | Syncope predicts the outcome of cardiomyopathy patients: analysis of the SCD-HeFT study. ( Anderson, J; Bardy, GH; Hellkamp, AS; Johnson, G; Lee, KL; Mark, DB; Olshansky, B; Packer, D; Poole, JE, 2008) |
| "Amiodarone is a Class III Vaughan-Williams anti-arrhythmic drug widely used in ventricular arrhythmias for its efficacy and low pro-arrhythmogenic effect." | 2.72 | Amiodarone in ventricular arrhythmias: still a valuable resource? ( Baldetti, L; Brugliera, L; Cianfanelli, L; D'Angelo, G; De Blasi, G; Della Bella, P; Falasconi, G; Frontera, A; Gulletta, S; Landoni, G; Malatino, L; Margonato, A; Melillo, F; Ossola, P; Pannone, L; Vergara, P; Zacchetti, D, 2021) |
| "Sudden cardiac death was observed in 16 patients, 8 patients in each group." | 2.72 | Determinants of sudden cardiac death in patients with persistent atrial fibrillation in the rate control versus electrical cardioversion (RACE) study. ( Crijns, HJ; Hagens, VE; Rienstra, M; Van Gelder, IC; Van Veldhuisen, DJ, 2006) |
| "Treatment with amiodarone or an implantable cardioverter-defibrillator (ICD) has been proposed to improve the prognosis in such patients." | 2.71 | Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. ( Anderson, J; Bardy, GH; Boineau, R; Clapp-Channing, N; Davidson-Ray, LD; Domanski, M; Fishbein, DP; Fraulo, ES; Ip, JH; Johnson, G; Lee, KL; Luceri, RM; Mark, DB; McNulty, SE; Packer, DL; Poole, JE; Troutman, C, 2005) |
| "Subgroups were also stratified by right bundle branch block and left bundle branch block, ejection fraction (EF) <30% and > or =30% to 40%, ischemic and nonischemic cardiomyopathy, amiodarone and placebo." | 2.70 | QRS duration and mortality in patients with congestive heart failure. ( Fisher, SG; Fletcher, RD; Iuliano, S; Karasik, PE; Singh, SN, 2002) |
| "Nonsustained ventricular tachycardia is frequently seen in patients with heart failure and may be associated with worsened survival by univariate analysis." | 2.69 | Prevalence and significance of nonsustained ventricular tachycardia in patients with premature ventricular contractions and heart failure treated with vasodilator therapy. Department of Veterans Affairs CHF STAT Investigators. ( Carson, PE; Fisher, SG; Fletcher, RD; Singh, SN, 1998) |
| "Amiodarone has been used widely in these patients but its value in preventing sudden death is still uncertain." | 2.69 | Nonsustained ventricular tachycardia as a predictor for sudden death in patients with idiopathic dilated cardiomyopathy. The role of amiodarone treatment. ( Castelli, G; Cecchi, F; Ciaccheri, M; Dolara, A; Marconi, P; Montereggi, A; Nannini, M; Olivotto, J; Troiani, V, 1999) |
| "Amiodarone was administered at a dosage of 800 mg/day for 2 weeks followed by 400 mg/day thereafter." | 2.68 | Effect of amiodarone therapy on mortality in patients with left ventricular dysfunction and asymptomatic complex ventricular arrhythmias: Argentine Pilot Study of Sudden Death and Amiodarone (EPAMSA). ( Gambarte, A; Garguichevich, JJ; Gentile, A; Hauad, S; Ramos, JL; Scapin, O; Sirena, J; Tibaldi, M; Toplikar, J, 1995) |
| "Amiodarone was judged effective in 7 patients by both tests (group I) and in 15 by either electrophysiologic study or Holter monitoring (group II)." | 2.68 | [Prediction of long-term efficacy of amiodarone for refractory ventricular tachycardia: clinical significance of electrophysiologic study and Holter monitoring]. ( Hosoda, S; Kasanuki, H; Ohnishi, S; Tsuchiya, M, 1996) |
| "A similar morning peak of sudden cardiac death was found in both the amiodarone (n = 42) and the placebo (n = 54) groups, and the overall circadian pattern did not differ between them (p = 0." | 2.68 | Effects of amiodarone on the circadian pattern of sudden cardiac death (Department of Veterans Affairs Congestive Heart Failure-Survival Trial of Antiarrhythmic Therapy). ( Behrens, S; Fisher, SG; Fletcher, RD; Franz, MR; Ney, G; Singh, SN, 1997) |
| "In 1987, the Cardiac Arrest Study Hamburg (CASH), a prospective, multicenter, randomized controlled study, was started in survivors of sudden cardiac death resulting from documented ventricular tachyarrhythmias." | 2.67 | Implantable cardioverter defibrillator compared with antiarrhythmic drug treatment in cardiac arrest survivors (the Cardiac Arrest Study Hamburg). ( Kuck, KH; Siebels, J, 1994) |
| "Amiodarone therapy was well tolerated in all but one patient." | 2.67 | [Risk stratification and long-term therapy with amiodarone in patients with idiopathic dilated cardiomyopathy]. ( Faber, T; Furtwängler, A; Hohnloser, S; Just, H; Meinertz, T; Zehender, M, 1992) |
| "Sudden cardiac death is a common cause of mortality in patients with congestive heart failure." | 2.67 | Prospective, double-blind, placebo-controlled trial of low-dose amiodarone in patients with severe heart failure and asymptomatic frequent ventricular ectopy. ( Das, SK; Krikler, SJ; McKenna, WJ; Mickelson, JK; Morady, F; Nicklas, JM; Pitt, B; Quain, LA; Schork, MA; Stewart, RA, 1991) |
| "Incessant ventricular tachycardia and "electrical storms" are emergencies, requiring urgent action in a close cooperation between critical care physicians and cardiologists." | 2.48 | [Incessant or recurrent ventricular tachycardia. Indications for emergency ablation]. ( Figulla, HR; Kühnert, H; Prochnau, D; Surber, R, 2012) |
| "Amiodarone is an antiarrhythmic medication used to treat and prevent certain types of serious, life-threatening ventricular arrhythmias." | 2.47 | Amiodarone supplants lidocaine in ACLS and CPR protocols. ( Camporesi, EM; Mangar, D; Mizzi, A; Tran, T, 2011) |
| "Not all patients at risk for sudden cardiac death (SCD) are eligible for, or have access to implantable cardioverter defibrillator (ICD) implantation." | 2.45 | Amiodarone for the prevention of sudden cardiac death: a meta-analysis of randomized controlled trials. ( Berger, JS; O'Connor, CM; Piccini, JP, 2009) |
| "Hypertrophic cardiomyopathy is a genetic disease that affects the cardiac sarcomere, resulting in myocardial hypertrophy and disarray." | 2.43 | Sudden death and hypertrophic cardiomyopathy: a review. ( Dubuc, M; Greiss, I; Guerra, PG; Ly, HQ; Macle, L; Roy, D; Talakic, M; Thibault, B, 2005) |
| "Sustained hemodynamically tolerated ventricular tachycardia (HTVT) comprises up to 30% of all cases of monomorphic ventricular tachycardia in patients with CAD." | 2.43 | Can amiodarone prevent sudden cardiac death in patients with hemodynamically tolerated sustained ventricular tachycardia and coronary artery disease? ( Arya, A; Haghjoo, M; Sadr-Ameli, MA, 2005) |
| "Sudden cardiac death is an elusive process that claims a significant number of lives annually in the United States." | 2.42 | Better living through chemistry: does it still apply to patients after myocardial infarction? ( Bobadilla, RV; Oppelt, TF, 2003) |
| "Amiodarone is a complicated drug, and its optimal use requires careful patient surveillance with respect to potential adverse effects." | 2.42 | Role of amiodarone in the era of the implantable cardioverter defibrillator. ( Dorian, P; Mangat, I, 2003) |
| "A wide spectrum of ventricular and supraventricular tachyarrhythmias occurs in the setting of congestive cardiac failure." | 2.41 | Significance and control of cardiac arrhythmias in patients with congestive cardiac failure. ( Singh, BN, 2002) |
| "Sudden cardiac death is a prominent feature of the natural history of heart disease." | 2.41 | Overview of randomized trials of antiarrhythmic drugs and devices for the prevention of sudden cardiac death. ( Heidenreich, PA; Hlatky, MA; Keeffe, B; McDonald, KM, 2002) |
| "amiodarone) because of atrial fibrillation or non-sustained VT that may activate the device." | 2.41 | Antiarrhythmic therapy in heart failure. ( Breithardt, G; Eckardt, L; Haverkamp, W, 2002) |
| "Amiodarone is an antiarrhythmic agent commonly used in the treatment of supraventricular and ventricular tachyarrhythmias." | 2.41 | Amiodarone: what have we learned from clinical trials? ( Dell'Orfano, JT; Luck, JC; Naccarelli, GV; Patel, HM; Wolbrette, DL, 2000) |
| "Further studies, including the Sudden Cardiac Death Heart Trial (SCD HeFT), should help determine the role of amiodarone in heart failure patients." | 2.40 | Amiodarone in congestive heart failure. ( Singh, S, 1998) |
| "Patients with congestive heart failure frequently have ventricular arrhythmias on ambulatory electrocardiographic recordings and sudden cardiac death is seen in almost 50% of such patients." | 2.40 | Class III drugs and congestive heart failure: focus on the congestive heart failure-survival trial of antiarrhythmic therapy. ( Fletcher, RD; Singh, SN, 1999) |
| "Right bundle branch block, persistent ST segment elevation in right precordial leads and sudden cardiac death, unexplainable by currently known disease, define a new distinct clinical and electrocardiographic syndrome." | 2.39 | Right bundle branch block, persistent ST-segment elevation in V1-V3 and sudden cardiac death: always a distinct syndrome? ( Boccalatte, A; Cuomo, S; D'Onofrio, A; Musto, B, 1995) |
| "Sotalol has not been widely studied in postinfarct patients; one trial indicated that the drug did reduce total mortality but the difference did not reach statistical significance." | 2.39 | Expanding indications for the use of Class III agents in patients at high risk for sudden death. ( Singh, BN, 1995) |
| "When the arrhythmia is symptomatic (sustained ventricular tachycardia or ventricular fibrillation), class I antiarrhythmics are not effective enough in the prevention of sudden death; betablockers and amiodarone may give good results but should be compared with implantable defibrillators in the future." | 2.39 | [Anti-arrhythmic therapy and cardiac failure]. ( Babuty, D; Charniot, JC; Cosnay, P; Fauchier, JP; Fauchier, L, 1995) |
| "The role of arrhythmias in the pathogenesis of sudden cardiac death in hypertrophic cardiomyopathy is reviewed together with the role of programmed ventricular stimulation." | 2.39 | Risk assessment and prevention of sudden cardiac death in hypertrophic cardiomyopathy. ( Camm, AJ; Slade, AK, 1996) |
| "Ventricular arrhythmia hypothesis was based on the thought that the patients' prognosis would be improved by suppression of ventricular arrhythmias with antiarrhythmic agents." | 2.39 | [Arrhythmias with normal heart rate]. ( Matsuo, H; Segawa, K; Yoshimoto, N, 1996) |
| "sustained ventricular tachycardia, ventricular fibrillation, aborted sudden cardiac death) are changing." | 2.39 | [Pharmacologic therapy of ventricular tachyarrhythmias: value of class III anti-arrhythmia drugs]. ( Block, M; Böcker, D; Borggrefe, M; Breithardt, G; Haverkamp, W, 1996) |
| "Amiodarone is a viable drug for preventing sudden cardiac death, particularly during the first year after MI." | 2.38 | Amiodarone and post-MI patients. ( Nademanee, K; Singh, BN; Stevenson, WG; Weiss, JN, 1993) |
| "Life-threatening ventricular tachyarrhythmias are the main reason for sudden cardiac death in coronary heart disease." | 2.38 | Pharmacological therapy in coronary heart disease: prevention of life-threatening ventricular tachyarrhythmias and sudden cardiac death. ( Eggeling, T; Hombach, V; Kochs, M, 1993) |
| "Amiodarone has been demonstrated to be an important and effective antiarrhythmic agent, as has sotalol." | 2.38 | Empiric use of amiodarone and sotalol. ( Nora, M; Zipes, DP, 1993) |
| " It should be stressed that the drug was administered at a low dosage level (200 mg/day) to 98 patients and did not cause serious side effects." | 2.38 | Secondary prevention after myocardial infarction with class III antiarrhythmic drugs. ( Ceremuzyński, L, 1993) |
| "Amiodarone has been shown to both increase and decrease the DFT." | 2.38 | Concomitant amiodarone and the implantable cardioverter-defibrillator: is there a place? ( McCollam, PL; Nappi, JM, 1993) |
| "Amiodarone was also more beneficial than individual antiarrhythmic therapy (mortality 10/100 patients, 10%)." | 2.38 | [What is the latest in anti-arrhythmia therapy?]. ( Gloor, HO, 1991) |
| "No sustained ventricular tachycardia, ventricular fibrillation, sudden cardiac death, or cardiovascular mortality were observed." | 1.72 | Propafenone use in coronary artery disease patients undergoing atrial fibrillation ablation. ( Aksu, T; Aras, D; Cay, S; Kara, M; Ozcan, F; Ozeke, O; Topaloglu, S, 2022) |
| " Previous literature has described fixed-dose propofol boluses and continuous infusions to convert ventricular arrhythmias; however, to our knowledge, there are no reports of a weight-based dosing strategy for VT." | 1.62 | Ventricular tachycardia converts to sinus rhythm after administration of propofol. ( Galletta, G; Li, I; Mokszycki, R; Saltzman, D; Shannon, K, 2021) |
| "Catecholaminergic polymorphic ventricular tachycardia (CPVT) is a rare but potentially lethal inherited arrhythmia syndrome induced by adrenergic stress." | 1.48 | A delayed diagnosis of catecholaminergic polymorphic ventricular tachycardia with a mutant of RYR2 at c.7580T>G for 6 years in a 9-year-old child. ( Duan, H; Hua, Y; Li, Y; Lu, Y; Qiao, L; Wang, C; Yan, S; Zhou, K, 2018) |
| "Severe ventricular arrhythmias are frequent during heart failure; they are a life-threatening condition due to the increased risk of sudden death." | 1.46 | [Severe ventricular arrhythmias in a patient with dilated cardiomyopathy and automated implantable defibrillator (AID)]. ( Ellenga-Mbolla, B; Gombet, TR; Ikama, SM; Kimbally-Kaky, G; Makani, J; Ondze-Kafata, LI, 2017) |
| "Hypertrophic cardiomyopathy is a frequent cause of sudden death." | 1.42 | Implantable Cardioverter-defibrillator Therapy for Hypertrophic Cardiomyopathy: Usefulness in Primary and Secondary Prevention. ( Alcalde, Ó; Anguera, I; Galve, E; García-Dorado, D; Moya, À; Núñez, E; Sabaté, X; Sarrias, A; Villuendas, R, 2015) |
| "Amiodarone was also used in 90% of the ICD group." | 1.40 | Implantable cardioverter-defibrillators for treatment of sustained ventricular arrhythmias in patients with Chagas' heart disease: comparison with a control group treated with amiodarone alone. ( Baggio, JM; Ferreira, LG; Gali, WL; Gomes, GG; Junqueira, LF; Marin-Neto, JA; Sarabanda, AV, 2014) |
| "Amiodarone and sotalol were found to have a neutral effect on survival." | 1.33 | Effect of concomitant antiarrhythmic therapy on survival in patients with implantable cardioverter defibrillators. ( Ho, AT; Pai, RG; Pai, SM; Timothy, P, 2005) |
| "Cardiac mortality and sudden cardiac death rates also were higher in group 3 patients." | 1.32 | Clinical usefulness of electrophysiologic testing in patients with ventricular tachycardia and chronic chagasic cardiomyopathy treated with amiodarone or sotalol. ( de Paola, AA; Fenelon, G; Friedman, PA; Leite, LR; Silva, GG; Simoes, A, 2003) |
| "Arrhythmogenic right ventricular dysplasia is an inherited, progressive condition." | 1.31 | Arrhythmogenic right ventricular dysplasia. An illustrated review highlighting developments in the diagnosis and management of this potentially fatal condition. ( Fisher, NG; Gilbert, TJ, 2000) |
| "In survivors of sudden cardiac deaths and other selected groups of patients, implantable cardioverter-defibrillators (ICDs) have been shown to have significant survival benefits in randomized controlled trials." | 1.31 | Are implantable cardioverter- defibrillators cost-effective? ( Naik, AM; Peter, CT, 2000) |
| "Amiodarone has been reported to reduce the likelihood of sudden death in patients with hypertrophic cardiomyopathy (HCM)." | 1.30 | Prognostic value of non-sustained ventricular tachycardia and the potential role of amiodarone treatment in hypertrophic cardiomyopathy: assessment in an unselected non-referral based patient population. ( Cecchi, F; Dolara, A; Maron, BJ; Montereggi, A; Olivotto, I; Squillatini, G, 1998) |
| "Amiodarone is a powerful suppressant of VPCs, but Holter suppression of this ectopic activity is not predictive of clinical outcome." | 1.29 | Usefulness of Holter monitoring in predicting efficacy of amiodarone therapy for sustained ventricular tachycardia associated with coronary artery disease. ( Doyle, TK; Nasir, N; Pacifico, A; Wheeler, SH, 1994) |
| "Patients with hypertrophic cardiomyopathy are traditionally thought to have increased sympathetic activity." | 1.29 | Is there increased sympathetic activity in patients with hypertrophic cardiomyopathy? ( Camm, AJ; Fei, L; Malik, M; McKenna, WJ; Prasad, K; Slade, AK, 1995) |
| "Amiodarone was prescribed orally at degressive doses." | 1.29 | [Predictive factors of induction of ventricular arrhythmia under amiodarone]. ( Bellon, C; Bonnefoy, E; Bouchayer, D; Bourret, N; Chevalier, P; Kirkorian, G; Richalet, C; Touboul, P, 1996) |
| "Non-sustained ventricular tachycardia occurs in 20% of patients and is the single best predictor of sudden death in adults." | 1.28 | Arrhythmia and hypertrophic cardiomyopathy. ( Keeling, PJ; McKenna, WJ; Shakespeare, CF; Slade, AK, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 106 (48.40) | 18.2507 |
| 2000's | 78 (35.62) | 29.6817 |
| 2010's | 28 (12.79) | 24.3611 |
| 2020's | 7 (3.20) | 2.80 |
| Authors | Studies |
|---|---|
| Pannone, L | 1 |
| D'Angelo, G | 1 |
| Gulletta, S | 1 |
| Falasconi, G | 1 |
| Brugliera, L | 1 |
| Frontera, A | 1 |
| Cianfanelli, L | 1 |
| Baldetti, L | 1 |
| Ossola, P | 1 |
| Melillo, F | 1 |
| De Blasi, G | 1 |
| Malatino, L | 1 |
| Landoni, G | 1 |
| Margonato, A | 1 |
| Della Bella, P | 1 |
| Zacchetti, D | 1 |
| Vergara, P | 1 |
| Hegwood, EC | 1 |
| Schaefer, E | 1 |
| Naccarelli, GV | 2 |
| Foy, AJ | 1 |
| Cay, S | 1 |
| Kara, M | 1 |
| Ozcan, F | 1 |
| Ozeke, O | 1 |
| Aksu, T | 1 |
| Aras, D | 1 |
| Topaloglu, S | 1 |
| Spears, J | 1 |
| Kowey, P | 1 |
| Rassi, FM | 1 |
| Minohara, L | 1 |
| Rassi, A | 3 |
| Correia, LCL | 1 |
| Marin-Neto, JA | 3 |
| da Silva Menezes, A | 1 |
| Mazzanti, A | 1 |
| Guz, D | 1 |
| Trancuccio, A | 1 |
| Pagan, E | 1 |
| Kukavica, D | 1 |
| Chargeishvili, T | 1 |
| Olivetti, N | 1 |
| Biernacka, EK | 1 |
| Sacilotto, L | 1 |
| Sarquella-Brugada, G | 1 |
| Campuzano, O | 1 |
| Nof, E | 1 |
| Anastasakis, A | 1 |
| Sansone, VA | 1 |
| Jimenez-Jaimez, J | 1 |
| Cruz, F | 1 |
| Sánchez-Quiñones, J | 1 |
| Hernandez-Afonso, J | 1 |
| Fuentes, ME | 1 |
| Średniawa, B | 1 |
| Garoufi, A | 1 |
| Andršová, I | 1 |
| Izquierdo, M | 1 |
| Marinov, R | 1 |
| Danon, A | 1 |
| Expósito-García, V | 1 |
| Garcia-Fernandez, A | 1 |
| Muñoz-Esparza, C | 1 |
| Ortíz, M | 1 |
| Zienciuk-Krajka, A | 1 |
| Tavazzani, E | 1 |
| Monteforte, N | 1 |
| Bloise, R | 1 |
| Marino, M | 1 |
| Memmi, M | 1 |
| Napolitano, C | 1 |
| Zorio, E | 1 |
| Monserrat, L | 1 |
| Bagnardi, V | 1 |
| Priori, SG | 1 |
| Poole, JE | 12 |
| Olshansky, B | 2 |
| Mark, DB | 14 |
| Anderson, J | 13 |
| Johnson, G | 8 |
| Hellkamp, AS | 9 |
| Davidson-Ray, L | 1 |
| Fishbein, DP | 4 |
| Boineau, RE | 1 |
| Anstrom, KJ | 1 |
| Reinhall, PG | 2 |
| Packer, DL | 4 |
| Lee, KL | 14 |
| Bardy, GH | 14 |
| Shannon, K | 1 |
| Saltzman, D | 1 |
| Li, I | 1 |
| Mokszycki, R | 1 |
| Galletta, G | 1 |
| Pokorney, SD | 1 |
| Mi, X | 1 |
| Hammill, BG | 1 |
| Allen LaPointe, NM | 1 |
| Curtis, LH | 1 |
| Al-Khatib, SM | 1 |
| Ikama, SM | 1 |
| Makani, J | 1 |
| Ellenga-Mbolla, B | 1 |
| Ondze-Kafata, LI | 1 |
| Gombet, TR | 1 |
| Kimbally-Kaky, G | 1 |
| da Silva, KR | 1 |
| Costa, R | 2 |
| Rodrigues, CG | 1 |
| Schasechter, A | 1 |
| Nobre, MC | 1 |
| Passman, R | 1 |
| Duan, H | 1 |
| Lu, Y | 1 |
| Yan, S | 1 |
| Qiao, L | 1 |
| Hua, Y | 1 |
| Li, Y | 2 |
| Zhou, K | 1 |
| Wang, C | 1 |
| Rørth, R | 1 |
| Dewan, P | 1 |
| Kristensen, SL | 1 |
| Jhund, PS | 1 |
| Petrie, MC | 1 |
| Køber, L | 1 |
| McMurray, JJV | 1 |
| Martinelli, M | 1 |
| de Paola, AA | 2 |
| Berwanger, O | 1 |
| Scanavacca, MI | 1 |
| Kalil, R | 1 |
| de Siqueira, SF | 1 |
| Gali, WL | 1 |
| Sarabanda, AV | 1 |
| Baggio, JM | 1 |
| Ferreira, LG | 1 |
| Gomes, GG | 1 |
| Junqueira, LF | 1 |
| Walsh, MN | 2 |
| Cadrin-Tourigny, J | 1 |
| Wyse, DG | 2 |
| Roy, D | 3 |
| Blondeau, L | 1 |
| Levesque, S | 1 |
| Talajic, M | 2 |
| Andrade, JG | 1 |
| Dubuc, M | 2 |
| Thibault, B | 2 |
| Guerra, PG | 2 |
| Macle, L | 2 |
| Rivard, L | 1 |
| Khairy, P | 1 |
| Sarrias, A | 1 |
| Galve, E | 1 |
| Sabaté, X | 1 |
| Moya, À | 1 |
| Anguera, I | 1 |
| Núñez, E | 1 |
| Villuendas, R | 1 |
| Alcalde, Ó | 1 |
| García-Dorado, D | 1 |
| Au-Yeung, WT | 1 |
| Fletcher, RD | 7 |
| Moore, HJ | 1 |
| Huikuri, HV | 2 |
| Claro, JC | 1 |
| Candia, R | 1 |
| Rada, G | 1 |
| Baraona, F | 1 |
| Larrondo, F | 1 |
| Letelier, LM | 1 |
| Meinertz, T | 2 |
| Saguil, A | 1 |
| Lelakowski, J | 1 |
| Rydlewska, A | 1 |
| Lelakowska, M | 1 |
| Pudło, J | 1 |
| Piekarz, J | 1 |
| Blatt, JA | 1 |
| Johnson, GW | 4 |
| Callans, DJ | 1 |
| Raitt, MH | 1 |
| Reddy, RK | 1 |
| Marchlinski, FE | 1 |
| Yee, R | 2 |
| Guarnieri, T | 1 |
| Wilber, DJ | 2 |
| Chung, K | 1 |
| Wong, WS | 1 |
| Curtis, AB | 2 |
| Hallstrom, AP | 2 |
| McAnulty, J | 1 |
| Gula, LJ | 1 |
| Klein, GJ | 2 |
| Massel, D | 1 |
| Krahn, AD | 1 |
| Skanes, AC | 1 |
| Deniz, HB | 1 |
| Ward, A | 1 |
| Jaime Caro, J | 1 |
| Alvarez, P | 1 |
| Sadri, H | 1 |
| Piccini, JP | 1 |
| Berger, JS | 1 |
| O'Connor, CM | 1 |
| Dai, SM | 1 |
| Zhang, S | 1 |
| Chen, KP | 1 |
| Hua, W | 1 |
| Wang, FZ | 1 |
| Chen, X | 1 |
| Levy, WC | 1 |
| Mozaffarian, D | 1 |
| Linker, DT | 1 |
| Maggioni, AP | 1 |
| Anand, I | 1 |
| Poole-Wilson, PA | 2 |
| Prutkin, JM | 1 |
| Mitchell, LB | 1 |
| Bernstein, RC | 1 |
| Wood, F | 1 |
| Boehmer, JP | 1 |
| Carlson, MD | 1 |
| Frantz, RP | 1 |
| McNulty, SE | 2 |
| Rogers, JG | 1 |
| Mishkin, JD | 1 |
| Saxonhouse, SJ | 1 |
| Woo, GW | 1 |
| Burkart, TA | 1 |
| Miles, WM | 2 |
| Conti, JB | 1 |
| Schofield, RS | 1 |
| Sears, SF | 1 |
| Aranda, JM | 1 |
| Dardas, TF | 1 |
| Aaronson, KD | 1 |
| Pinamonti, B | 1 |
| Dragos, AM | 1 |
| Pyxaras, SA | 1 |
| Merlo, M | 1 |
| Pivetta, A | 1 |
| Barbati, G | 1 |
| Di Lenarda, A | 2 |
| Morgera, T | 1 |
| Mestroni, L | 1 |
| Sinagra, G | 1 |
| Lang, ES | 1 |
| Browning, K | 1 |
| Droogan, C | 1 |
| Patel, C | 1 |
| Yan, GX | 1 |
| Kowey, PR | 3 |
| Ayalloore, SG | 1 |
| LeLorier, P | 1 |
| Mizzi, A | 1 |
| Tran, T | 1 |
| Mangar, D | 1 |
| Camporesi, EM | 1 |
| Crijns, HJ | 3 |
| Aliot, EM | 1 |
| Capucci, A | 1 |
| Kulakowski, P | 1 |
| Radzik, D | 1 |
| Connolly, SJ | 3 |
| Hohnloser, SH | 2 |
| Santangeli, P | 1 |
| Di Biase, L | 1 |
| Burkhardt, JD | 1 |
| Bai, R | 1 |
| Mohanty, P | 1 |
| Pump, A | 1 |
| Natale, A | 1 |
| Jadoul, M | 1 |
| Thumma, J | 1 |
| Fuller, DS | 1 |
| Tentori, F | 1 |
| Morgenstern, H | 1 |
| Mendelssohn, D | 1 |
| Tomo, T | 1 |
| Ethier, J | 1 |
| Port, F | 1 |
| Robinson, BM | 1 |
| Surber, R | 1 |
| Prochnau, D | 1 |
| Kühnert, H | 1 |
| Figulla, HR | 1 |
| Daidoji, H | 1 |
| Arimoto, T | 1 |
| Nitobe, J | 1 |
| Tamura, H | 1 |
| Kutsuzawa, D | 1 |
| Ishigaki, D | 1 |
| Ishino, M | 1 |
| Takahashi, H | 1 |
| Shishido, T | 1 |
| Miyashita, T | 1 |
| Miyamoto, T | 1 |
| Watanabe, T | 1 |
| Kubota, I | 1 |
| Yonezawa, M | 1 |
| Komuro, I | 1 |
| Kaneko, Y | 1 |
| Kurabayashi, M | 1 |
| Singh, BN | 5 |
| Heidenreich, PA | 4 |
| Keeffe, B | 1 |
| McDonald, KM | 4 |
| Hlatky, MA | 4 |
| Owens, DK | 3 |
| Sanders, GD | 3 |
| Grönefeld, GC | 1 |
| Grimm, W | 3 |
| Maisch, B | 2 |
| Eckardt, L | 1 |
| Haverkamp, W | 2 |
| Breithardt, G | 3 |
| Favale, S | 1 |
| Pappone, C | 1 |
| Nacci, F | 1 |
| Fino, F | 1 |
| Resta, F | 1 |
| Dicandia, CD | 1 |
| Prystowsky, EN | 1 |
| Oppelt, TF | 1 |
| Bobadilla, RV | 1 |
| Leite, LR | 1 |
| Fenelon, G | 1 |
| Simoes, A | 1 |
| Silva, GG | 1 |
| Friedman, PA | 1 |
| Exner, DV | 2 |
| Dorian, P | 3 |
| Mangat, I | 2 |
| Ball, TA | 1 |
| Kerns, JW | 1 |
| Nashelsky, J | 1 |
| Saseen, J | 1 |
| Srivatsa, UN | 1 |
| Ebrahimi, R | 1 |
| El-Bialy, A | 1 |
| Wachsner, RY | 1 |
| Seggewiss, H | 1 |
| Rigopoulos, A | 1 |
| Kwok, KM | 1 |
| Lau, CP | 1 |
| Tse, HF | 1 |
| Doggrell, SA | 1 |
| Shinde, AA | 1 |
| Juneman, EB | 1 |
| Mitchell, B | 1 |
| Pierce, MK | 1 |
| Gaballa, MA | 1 |
| Goldman, S | 1 |
| Thai, H | 1 |
| Lau, EW | 1 |
| Griffith, MJ | 1 |
| Pathmanathan, RK | 1 |
| Ng, GA | 1 |
| Clune, MM | 1 |
| Cooper, J | 1 |
| Marshall, HJ | 1 |
| Forsey, PR | 1 |
| Stafford, PJ | 1 |
| Gray, RG | 1 |
| Skehan, JD | 1 |
| Garratt, CJ | 1 |
| Raczak, G | 1 |
| Pinna, GD | 1 |
| Maestri, R | 1 |
| Daniłowicz-Szymanowicz, L | 1 |
| Szwoch, M | 1 |
| Lubinski, A | 1 |
| Kempa, M | 1 |
| La Rovere, MT | 1 |
| Swiatecka, G | 1 |
| Bokhari, F | 1 |
| Newman, D | 1 |
| Greene, M | 1 |
| Korley, V | 1 |
| Wellens, HJ | 2 |
| Kanopskiĭ, SG | 1 |
| Staritskiĭ, AG | 1 |
| Bozhko, AA | 1 |
| Boineau, R | 1 |
| Domanski, M | 3 |
| Troutman, C | 1 |
| Clapp-Channing, N | 1 |
| Davidson-Ray, LD | 1 |
| Fraulo, ES | 1 |
| Luceri, RM | 1 |
| Ip, JH | 1 |
| Boriani, G | 1 |
| Biffi, M | 1 |
| Martignani, C | 1 |
| Ly, HQ | 1 |
| Greiss, I | 1 |
| Talakic, M | 1 |
| Ho, AT | 1 |
| Pai, SM | 1 |
| Timothy, P | 1 |
| Pai, RG | 1 |
| Arya, A | 1 |
| Haghjoo, M | 1 |
| Sadr-Ameli, MA | 1 |
| Borggrefe, M | 2 |
| Wolpert, C | 1 |
| Otsuka, T | 1 |
| Yamashita, T | 1 |
| Elliott, PM | 2 |
| Gimeno, JR | 1 |
| Tomé, MT | 1 |
| Shah, J | 1 |
| Ward, D | 1 |
| Thaman, R | 1 |
| Mogensen, J | 1 |
| McKenna, WJ | 6 |
| Hagens, VE | 1 |
| Rienstra, M | 1 |
| Van Veldhuisen, DJ | 2 |
| Van Gelder, IC | 1 |
| Mindel, JS | 1 |
| Hellkamp, A | 1 |
| Freudenberger, RS | 1 |
| Halperin, JL | 1 |
| Poole, J | 1 |
| Melacini, P | 2 |
| Maron, BJ | 3 |
| Bobbo, F | 1 |
| Basso, C | 1 |
| Tokajuk, B | 1 |
| Zucchetto, M | 1 |
| Thiene, G | 1 |
| Iliceto, S | 1 |
| Shiga, T | 1 |
| Hagiwara, N | 1 |
| Kasanuki, H | 5 |
| Nakamura, K | 1 |
| Nishii, N | 1 |
| Ohe, T | 1 |
| Torp-Pedersen, C | 1 |
| Metra, M | 1 |
| Spark, P | 1 |
| Lukas, MA | 1 |
| Moullet, C | 1 |
| Scherhag, A | 1 |
| Komajda, M | 1 |
| Cleland, JG | 1 |
| Remme, W | 1 |
| Swedberg, K | 1 |
| Worck, R | 1 |
| Haarbo, J | 1 |
| Thomsen, PE | 1 |
| Mitchell, JE | 1 |
| Packer, D | 1 |
| Russo, AM | 1 |
| Lima, CE | 1 |
| Martinelli Filho, M | 1 |
| Silva, RT | 1 |
| Tamaki, WT | 1 |
| Oliveira, JC | 1 |
| Martins, DC | 1 |
| Nishióka, SA | 1 |
| Pedrosa, AA | 1 |
| Siqueira, SF | 1 |
| Zarembski, DG | 1 |
| Nolan, PE | 1 |
| Slack, MK | 1 |
| Caruso, AC | 1 |
| Navarro-López, F | 1 |
| Cosin, J | 1 |
| Marrugat, J | 1 |
| Guindo, J | 1 |
| Bayes de Luna, A | 1 |
| Nasir, N | 1 |
| Doyle, TK | 1 |
| Wheeler, SH | 1 |
| Pacifico, A | 1 |
| Singh, SN | 7 |
| Fisher, SG | 5 |
| Lewis, HD | 1 |
| Deedwania, PC | 1 |
| Massie, BM | 1 |
| Colling, C | 1 |
| Lazzeri, D | 1 |
| Cardim, N | 1 |
| Longo, S | 1 |
| Gouveia, D | 1 |
| Lousada, N | 1 |
| Ferreira, T | 1 |
| Pereira, AT | 1 |
| Correia, JM | 1 |
| Fei, L | 2 |
| Slade, AK | 4 |
| Prasad, K | 2 |
| Malik, M | 2 |
| Camm, AJ | 5 |
| Szabó, BM | 1 |
| Wiesfeld, AC | 1 |
| Hillege, HL | 1 |
| Lie, KI | 1 |
| Ahmad, S | 1 |
| Middlekauff, HR | 2 |
| Stevenson, WG | 4 |
| Saxon, LA | 2 |
| Stevenson, LW | 2 |
| Garguichevich, JJ | 1 |
| Ramos, JL | 1 |
| Gambarte, A | 1 |
| Gentile, A | 1 |
| Hauad, S | 1 |
| Scapin, O | 3 |
| Sirena, J | 1 |
| Tibaldi, M | 1 |
| Toplikar, J | 1 |
| Siebels, J | 4 |
| Cappato, R | 3 |
| Rüppel, R | 2 |
| Schneider, MA | 2 |
| Kuck, KH | 6 |
| Nademanee, K | 2 |
| Weiss, JN | 1 |
| Inaba, T | 1 |
| Ohnisi, S | 1 |
| Shoda, M | 1 |
| Matuda, N | 1 |
| Hosoda, S | 3 |
| Grace, AA | 1 |
| Doval, HC | 3 |
| Nul, DR | 3 |
| Grancelli, HO | 3 |
| Perrone, SV | 3 |
| Bortman, GR | 1 |
| Curiel, R | 1 |
| Jolobe, OM | 1 |
| Antimisiaris, M | 1 |
| Sarma, JS | 1 |
| Schoenbaum, MP | 1 |
| Sharma, PP | 1 |
| Venkataraman, K | 1 |
| Djian, J | 1 |
| Schwartz, PJ | 2 |
| Frangin, G | 2 |
| Janse, MJ | 2 |
| Julian, DG | 2 |
| Simon, P | 2 |
| Proclemer, A | 1 |
| Facchin, D | 1 |
| Feruglio, GA | 1 |
| Nucifora, R | 1 |
| Buja, G | 1 |
| Miorelli, M | 1 |
| Turrini, P | 1 |
| Nava, A | 1 |
| Kochs, M | 1 |
| Eggeling, T | 1 |
| Hombach, V | 1 |
| Nora, M | 1 |
| Zipes, DP | 3 |
| Ceremuzyński, L | 1 |
| McCollam, PL | 1 |
| Nappi, JM | 1 |
| Weinberg, BA | 1 |
| Klein, LS | 1 |
| Bolander, JE | 1 |
| Dusman, RE | 1 |
| Stanton, MS | 1 |
| Heger, JJ | 1 |
| Langefeld, C | 1 |
| Pfisterer, ME | 1 |
| Kiowski, W | 2 |
| Brunner, H | 2 |
| Burckhardt, D | 3 |
| Burkart, F | 2 |
| Malden, ES | 1 |
| Tartar, VM | 1 |
| Gutierrez, FR | 1 |
| Olson, PJ | 1 |
| Woelfel, A | 1 |
| Simpson, RJ | 1 |
| Foster, JR | 1 |
| Pfisterer, M | 2 |
| D'Onofrio, A | 1 |
| Cuomo, S | 1 |
| Musto, B | 1 |
| Boccalatte, A | 1 |
| Sleight, P | 1 |
| Finance, O | 1 |
| Manning, A | 1 |
| Chatelain, P | 1 |
| Rodríguez, LM | 1 |
| Sternick, EB | 1 |
| Smeets, JL | 1 |
| Timmermans, C | 1 |
| den Dulk, K | 1 |
| Oreto, G | 1 |
| Hammill, SC | 1 |
| Ridker, PM | 1 |
| Cosnay, P | 1 |
| Babuty, D | 1 |
| Charniot, JC | 1 |
| Fauchier, L | 1 |
| Fauchier, JP | 1 |
| Fleurant, E | 1 |
| Lacroix, D | 1 |
| Klug, D | 1 |
| Warembourg, H | 1 |
| Kacet, S | 1 |
| Lekieffre, J | 1 |
| Segawa, K | 1 |
| Yoshimoto, N | 1 |
| Matsuo, H | 1 |
| Fogoros, RN | 3 |
| Bourret, N | 1 |
| Kirkorian, G | 1 |
| Chevalier, P | 1 |
| Bellon, C | 1 |
| Richalet, C | 1 |
| Bouchayer, D | 1 |
| Bonnefoy, E | 1 |
| Touboul, P | 1 |
| Tsuchiya, M | 1 |
| Ohnishi, S | 2 |
| Takeichi, K | 1 |
| Endoh, Y | 1 |
| Varini, SD | 2 |
| Soifer, S | 2 |
| Corrado, G | 1 |
| Dubner, S | 1 |
| Harris, RA | 1 |
| Dembitzer, AD | 1 |
| Steder, U | 1 |
| Menz, V | 1 |
| Hoffmann, J | 1 |
| Block, M | 1 |
| Böcker, D | 2 |
| Munoz, A | 2 |
| Cairns, JA | 1 |
| Roberts, R | 1 |
| Gent, M | 2 |
| Prieto, N | 1 |
| Behrens, S | 1 |
| Ney, G | 1 |
| Franz, MR | 1 |
| McAlister, FA | 1 |
| Teo, KK | 2 |
| Villain, E | 1 |
| Waldo, AL | 1 |
| Weisfeldt, ML | 1 |
| Giorgberidze, I | 1 |
| Saksena, S | 1 |
| Krol, RB | 1 |
| Munsif, AN | 1 |
| Kolettis, T | 1 |
| Mathew, P | 1 |
| Varanasi, S | 1 |
| Prakash, A | 1 |
| Delfaut, P | 1 |
| Lewis, CB | 1 |
| Kall, JG | 1 |
| Kopp, DE | 1 |
| Veerakul, G | 1 |
| Nimmannit, S | 1 |
| Chaowakul, V | 1 |
| Bhuripanyo, K | 1 |
| Likittanasombat, K | 1 |
| Tunsanga, K | 1 |
| Kuasirikul, S | 1 |
| Malasit, P | 1 |
| Tansupasawadikul, S | 1 |
| Tatsanavivat, P | 1 |
| Campbell, TJ | 1 |
| Landray, MJ | 1 |
| Kendall, MJ | 1 |
| Brugada, J | 1 |
| Brugada, R | 1 |
| Brugada, P | 1 |
| van Daele, ME | 1 |
| Berger, RM | 1 |
| Smeets, J | 1 |
| Hess, J | 1 |
| Frenneaux, MP | 1 |
| Cecchi, F | 2 |
| Olivotto, I | 1 |
| Montereggi, A | 2 |
| Squillatini, G | 1 |
| Dolara, A | 2 |
| Hutcheson, J | 1 |
| Peters, CA | 1 |
| Diamond, DA | 1 |
| Carson, PE | 1 |
| Humphries, JO | 1 |
| Singh, S | 1 |
| Domanski, MJ | 2 |
| Farré, J | 1 |
| Romero, J | 1 |
| Rubio, JM | 1 |
| Ayala, R | 1 |
| Castro-Dorticós, J | 1 |
| Klein, H | 1 |
| Auricchio, A | 2 |
| Reek, S | 1 |
| Geller, C | 1 |
| Ferrari, R | 1 |
| Cinca, J | 1 |
| Marber, M | 1 |
| Sharma, S | 1 |
| Varnava, A | 1 |
| Poloniecki, J | 1 |
| Rowland, E | 1 |
| Castelli, G | 1 |
| Ciaccheri, M | 1 |
| Troiani, V | 1 |
| Nannini, M | 1 |
| Marconi, P | 1 |
| Olivotto, J | 1 |
| Kausar, SA | 1 |
| Zivin, A | 1 |
| Naccarella, F | 1 |
| Lepera, G | 1 |
| Rolli, A | 1 |
| Wolbrette, DL | 1 |
| Dell'Orfano, JT | 1 |
| Patel, HM | 1 |
| Luck, JC | 1 |
| Fisher, NG | 1 |
| Gilbert, TJ | 1 |
| Copie, X | 1 |
| Piot, O | 1 |
| Said, MA | 1 |
| Lavergne, T | 1 |
| Ollitrault, J | 1 |
| Guize, L | 1 |
| Le Heuzey, JY | 1 |
| Naik, AM | 1 |
| Peter, CT | 1 |
| Myerburg, RJ | 2 |
| Cooley, R | 1 |
| Akhtar, M | 1 |
| Sra, J | 1 |
| Frankenberger, O | 1 |
| Steinberg, JS | 1 |
| Schmitt, C | 1 |
| Schron, EB | 1 |
| Greene, HL | 1 |
| Boczor, S | 1 |
| Follmann, D | 1 |
| Roberts, RS | 1 |
| Nisam, S | 1 |
| Klein, HU | 1 |
| Cosín Aguilar, J | 1 |
| Hernándiz Martínez, A | 1 |
| Every, NR | 1 |
| Parsons, LS | 1 |
| Castellanos, A | 1 |
| Gronda, E | 1 |
| Mangiavacchi, M | 1 |
| Andreuzzi, B | 1 |
| Municinò, A | 1 |
| Mookadam, F | 1 |
| Nägele, H | 1 |
| Schomburg, R | 1 |
| Petersen, B | 1 |
| Rödiger, W | 1 |
| Schläpfer, J | 1 |
| Rapp, F | 1 |
| Kappenberger, L | 1 |
| Fromer, M | 1 |
| Alboni, P | 1 |
| Iuliano, S | 1 |
| Karasik, PE | 1 |
| Bilchick, KC | 1 |
| Fetics, B | 1 |
| Djoukeng, R | 1 |
| Nevo, E | 1 |
| Berger, RD | 1 |
| Shakespeare, CF | 1 |
| Keeling, PJ | 1 |
| Handlin, LR | 1 |
| Brodine, WN | 1 |
| Gibbs, H | 1 |
| Vacek, JL | 1 |
| O'Brien, BJ | 1 |
| Buxton, MJ | 1 |
| Rushby, JA | 1 |
| Herms, J | 1 |
| Schneider, M | 1 |
| Zehender, M | 1 |
| Faber, T | 1 |
| Furtwängler, A | 1 |
| Hohnloser, S | 1 |
| Just, H | 1 |
| Larsen, GC | 1 |
| Manolis, AS | 1 |
| Sonnenberg, FA | 1 |
| Beshansky, JR | 1 |
| Estes, NA | 1 |
| Pauker, SG | 1 |
| Gloor, HO | 1 |
| Robertson, A | 1 |
| Hoffmann, A | 1 |
| Bennett, BH | 1 |
| Kerin, NZ | 1 |
| Frumin, H | 1 |
| Faitel, K | 1 |
| Aragon, E | 1 |
| Rubenfire, M | 1 |
| Pathé, M | 1 |
| Kahn, JC | 1 |
| Nicklas, JM | 1 |
| Stewart, RA | 1 |
| Mickelson, JK | 1 |
| Das, SK | 1 |
| Schork, MA | 1 |
| Krikler, SJ | 1 |
| Quain, LA | 1 |
| Morady, F | 1 |
| Pitt, B | 1 |
| Nalos, PC | 1 |
| Ismail, Y | 1 |
| Pappas, JM | 1 |
| Nyitray, W | 1 |
| DonMichael, TA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Sudden Cardiac Death in Heart Failure Trial 10 Year Follow-up (SCD-HeFT 10 Year)[NCT01058837] | 1,855 participants (Anticipated) | Observational | 2009-09-30 | Active, not recruiting | |||
| CHronic Use of Amiodarone aGAinSt Implantable Cardioverter-defibrillator Therapy for Primary Prevention of Death in Patients With Chagas Cardiomyopathy Study (CHAGASICS)[NCT01722942] | 1,100 participants (Anticipated) | Interventional | 2014-10-06 | Recruiting | |||
| [NCT00000609] | Phase 3 | 0 participants | Interventional | 1997-05-31 | Completed | ||
| Pragmatic Randomized Clinical Trial of Early Dronedarone Versus Usual Care to Change and Improve Outcomes in Persons With First-Detected Atrial Fibrillation[NCT05130268] | Phase 4 | 3,000 participants (Anticipated) | Interventional | 2021-10-29 | Active, not recruiting | ||
| "Test-No Test Implantable Cardioverter Defibrillator Pilot Study (TNT-ICD)"[NCT01905007] | Phase 4 | 100 participants (Anticipated) | Interventional | 2010-12-31 | Recruiting | ||
| Acute Mechanical Response to Anti-arrhythmic Drug Therapy[NCT02575534] | 0 participants (Actual) | Interventional | 2015-10-31 | Withdrawn (stopped due to No enrollment in study.) | |||
| Double Blind Placebo Controlled Dose Ranging Study of the Efficacy and Safety of Celivarone at 50, 100 or 300 mg OD With Amiodarone as Calibrator for the Prevention of ICD Interventions or Death[NCT00993382] | Phase 2 | 486 participants (Actual) | Interventional | 2009-09-30 | Completed | ||
| Development of a Mathematical Model for the Evaluation of the Potassium Kinetic During and After Hemodialysis for the Potassium Profiling in the Dialysate to Prevent Arrhythmias[NCT04563091] | 6 participants (Anticipated) | Interventional | 2018-11-15 | Recruiting | |||
| ECG Device for Long QT Syndrome Screening in Newborns[NCT02412709] | Phase 2 | 4,000 participants (Anticipated) | Interventional | 2015-06-30 | Recruiting | ||
| Endocardial-Epicardial Radiofrequency Ablation of Ventricular Tachycardia in Patients With Ischemic Cardiomyopathy[NCT04512911] | Early Phase 1 | 0 participants (Actual) | Interventional | 2023-01-31 | Withdrawn (stopped due to IRB approval expired 1/23/2023 and eclipsed the 6 month institutional window where study can be reinitiated via progress report. No enrollment has taken place.) | ||
| A Pilot Trial of Patient Decision Aids for Implantable Cardioverter-Defibrillators (ICDs)[NCT02026102] | 15 participants (Actual) | Interventional | 2014-09-30 | Completed | |||
| CRT-P or CRT-D in Patients With Dilated Cardiomyopathy and Heart Failure Without LGE-CMR High-risk Markers[NCT04139460] | 924 participants (Anticipated) | Interventional | 2020-06-30 | Not yet recruiting | |||
| VOYAGE- Ventricular Tachycardia Ablation and Myocardial Scar Characterization With Magnetic Resonance[NCT04694079] | Phase 3 | 103 participants (Anticipated) | Interventional | 2020-08-03 | Recruiting | ||
| Sodium Channel Splicing in Heart Failure Trial (SOCS-HEFT) Prospective Study[NCT02738749] | 450 participants (Anticipated) | Interventional | 2014-06-30 | Recruiting | |||
| OMNI Study--Assessing Therapies in Medtronic Pacemaker, Defibrillator, and Cardiac Resynchronization Therapy Devices.[NCT00277524] | 3,032 participants (Actual) | Observational | 2005-08-31 | Terminated (stopped due to Ended follow-up after four years) | |||
| Comparative Effectiveness Research to Assess the Use of Primary ProphylacTic Implantable Cardioverter Defibrillators in Europe[NCT02064192] | 2,285 participants (Actual) | Observational | 2014-05-31 | Completed | |||
| CMR Based Prediction of Ventricular Tachycardia Events in Healed Myocardial Infarction (DEVELOP-VT)[NCT04599439] | 1,000 participants (Anticipated) | Observational [Patient Registry] | 2020-08-01 | Recruiting | |||
| An Intervention to Improve ICD Deactivation Conversations (WISDOM - Working to Improve discuSsions About DefibrillatOr Management)[NCT01459744] | 562 participants (Actual) | Interventional | 2011-09-30 | Completed | |||
| Catheter Ablation for Ventricular Tachycardia in Patients With an Implantable Cardioverter Defibrillator (CALYPSO) PILOT TRIAL[NCT01576042] | 27 participants (Actual) | Interventional | 2012-05-31 | Terminated (stopped due to Main objectives of the study were met; consensus among investigators that continuing the study would not add new information beyond that already learned.) | |||
| Preventive VT Substrate Ablation in Patients With Chronic Post-MI Scar Showing Arrhythmogenic Characteristics[NCT04675073] | Phase 3 | 58 participants (Anticipated) | Interventional | 2021-06-01 | Recruiting | ||
| [NCT00000531] | Phase 3 | 0 participants | Interventional | 1992-09-30 | Completed | ||
| Discovering the Genetic Causes of Brugada Syndrome in Thais and Southeast Asian Population[NCT04232787] | 750 participants (Anticipated) | Observational [Patient Registry] | 2016-01-28 | Recruiting | |||
| EvaLuation Using Cardiac Insertable Devices And TelephonE in Hypertrophic CardioMyopathy[NCT03259113] | 30 participants (Anticipated) | Interventional | 2017-08-16 | Recruiting | |||
| STereotactic Ablative Radiosurgery of Recurrent Ventricular Tachycardia in Structural Heart Disease[NCT03819504] | 0 participants (Actual) | Interventional | 2018-08-01 | Withdrawn (stopped due to Change in the design of the study) | |||
| Phase I/II Study of 4-D Navigated Non-invasive Radiosurgical Ablation of Ventricular Tachycardia[NCT03601832] | 10 participants (Actual) | Interventional | 2018-08-01 | Completed | |||
| STereotactic Ablative Radiosurgery of Recurrent Ventricular Tachycardia in Structural Heart Disease[NCT04612140] | 100 participants (Actual) | Interventional | 2020-10-01 | Completed | |||
| Characterization of Cardiac Arrhythmias in End Stage Kidney Disease Patients on Hemodialysis Using an Implantable Continuous Cardiac Rhythm Monitoring Device: A Pilot Study[NCT00932659] | 8 participants (Actual) | Observational | 2009-06-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"First shock rate for VF and FVT zones was estimated using Kaplan-Meier method.~OMNI PainFREE definition: programming combinations that result in ATP therapy for ventricular tachycardia (VT) at cycle lengths <320 ms. Programming at cycle lengths ≥320 ms were not mandated.~OMNI SCD-HeFT definition: programming combinations that result in shock therapy only for arrhythmias at cycle lengths of <320 ms or faster and no therapy for arrhythmias at cycle lengths ≥320 ms." (NCT00277524)
Timeframe: 4 years post implant
| Intervention | rate (Mean) | ||||
|---|---|---|---|---|---|
| At implant | 12 months after implant | 24 months after implant | 36 months after implant | 48 months after implant | |
| "PainFREE Programming" | 0 | 0.10 | 0.14 | 0.18 | 0.20 |
| "SCD-HeFT Programming" | 0 | 0.15 | 0.21 | 0.24 | 0.27 |
Frequencies of subject with AV block over time between ICD and Implantable Pulse Generator(IPG) study participants. (NCT00277524)
Timeframe: 12 months post enrollment
| Intervention | participants (Number) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 6 Months: Subjects with MVP enabled, N | 6 Months: AV Block 1st degree | 6 Months: AV Block 2nd degree Type I | 6 Months: AV Block 2nd degree Type II | 6 Months: AV Block 3rd degree Intermittent | 6 Months: AV Block 3rd degree Persistent | 6 Months: None | 12 Months: Subjects with MVP enabled, N | 12 Months: AV Block 1st degree | 12 Months: AV Block 2nd degree Type I | 12 Months: AV Block 2nd degree Type II | 12 Months: AV Block 3rd degree Intermittent | 12 Months: AV Block 3rd degree Persistent | 12 Months: None | |
| ICD (N=1029) | 815 | 167 | 7 | 7 | 5 | 5 | 603 | 732 | 159 | 7 | 7 | 5 | 7 | 523 |
| IPG (N=610) | 441 | 103 | 11 | 19 | 39 | 11 | 250 | 389 | 90 | 12 | 7 | 30 | 14 | 216 |
Frequencies of Subjects with AV Block Over Time by Severity of Historical AV Block (NCT00277524)
Timeframe: 4 years post implant
| Intervention | participants (Number) | ||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 6 Months: Subjects with MVP enabled | 6 Months: AV Block 1st degree | 6 Months: AV Block 2nd degree Type I | 6 Months: AV Block 2nd degree Type II | 6 Months: AV Block 3rd degree Intermittent | 6 Months: AV Block 3rd degree Persistent | 6 Months: None | 12 Months: Subjects with MVP enabled | 12 Months: AV Block 1st degree | 12 Months: AV Block 2nd degree Type I | 12 Months: AV Block 2nd degree Type II | 12 Months: AV Block 3rd degree Intermittent | 12 Months: AV Block 3rd degree Persistent | 12 Months: None | 24 Months: Subjects with MVP enabled | 24 Months: AV Block 1st degree | 24 Months: AV Block 2nd degree Type I | 24 Months: AV Block 2nd degree Type II | 24 Months: AV Block 3rd degree Intermittent | 24 Months: AV Block 3rd degree Persistent | 24 Months: None | 36 Months: Subjects with MVP enabled | 36 Months: AV Block 1st degree | 36 Months: AV Block 2nd degree Type I | 36 Months: AV Block 2nd degree Type II | 36 Months: AV Block 3rd degree Intermittent | 36 Months: AV Block 3rd degree Persistent | 36 Months: None | 48 Months: Subjects with MVP enabled | 48 Months: AV Block 1st degree | 48 Months: AV Block 2nd degree Type I | 48 Months: AV Block 2nd degree Type II | 48 Months: AV Block 3rd degree Intermittent | 48 Months: AV Block 3rd degree Persistent | 48 Months: None | |
| Patients With History of AV Block | 373 | 221 | 17 | 25 | 42 | 13 | 35 | 335 | 176 | 19 | 13 | 30 | 18 | 50 | 146 | 95 | 5 | 3 | 3 | 2 | 24 | 105 | 69 | 3 | 2 | 3 | 2 | 18 | 92 | 59 | 2 | 1 | 2 | 2 | 17 |
| Patients Without History of AV Block | 883 | 49 | 1 | 1 | 2 | 3 | 818 | 786 | 73 | 0 | 1 | 5 | 3 | 689 | 426 | 51 | 0 | 0 | 1 | 0 | 362 | 324 | 58 | 1 | 0 | 0 | 0 | 253 | 269 | 59 | 0 | 0 | 0 | 1 | 201 |
"Estimate the correlation between OptiVol trends and disease progression.~A subject's disease status was said to have progressed if:~The NYHA classification number increases (example: I to II), or~The LVEF decreases by at least 20% (relative difference) and by at least a 5% absolute difference, or~The subject expires~A subject who crossed OptiVol threshold since last visit was regarded as 'crossed threshold'." (NCT00277524)
Timeframe: 4 years post implant
| Intervention | participants (Number) | |
|---|---|---|
| Disease Progressed, N | Crossed Threshold, N | |
| 12-month Follow-up | 97 | 382 |
| 24-month Follow-up | 95 | 327 |
| 36-month Follow-up | 93 | 287 |
| 48-month Follow-up | 84 | 224 |
ICD/CRT-D baseline programming, pacing mode and detection. Pacing mode is based on the NASPE/BPEG Generic (NBG) Pacemake coding which includes: I, the chambers paced (V= Ventricle, A=Atrium, D=Dual (A&V), O=None); II, the chambers sensed (V= Ventricle, A=Atrium, D=Dual (A&V), O=None); III, the mode of response (T=Triggered, I=Inhibited, D=Dual Triggered/Inhibited, O=None); IV, the programmable functions(R=Rate Modulated, C=Communicating, M=Multiprogrammable, P=Simple Programmable, O=None); V, the antitachycardia functions (O=None, P=Paced, S=Shocks, D=Dual (P&S)). In addition, MVP (managed ventricular pacing) is a mode that promotes AV conduction by reducing or eliminating unnecessary RV pacing but maintains dual chamber ventricular support in the event that AV conduction is lost. (NCT00277524)
Timeframe: Baseline
| Intervention | participants (Number) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pacing Mode, DDD/DDDR | Pacing Mode, DDI/DDIR | Pacing Mode, MVP_AAIR_DD | Pacing Mode, MVP_AAI_DDD | Pacing Mode, VVI/VVIR | ATP Status, Before Charging | ATP Status, During Charging | ATP Status, Off | VF Detection Enable, On | VT Detection Enable, On | VT Detection Enable, Monitor | VF Initial NID, 12/16 | VF Initial NID, 18/24 | VF Initial NID, 24/32 | FVT Detection On via VF zone | FVT Detection On via VT zone | |
| ICD/CRT-D Group | 804 | 21 | 525 | 481 | 424 | 23 | 1089 | 26 | 2234 | 1283 | 345 | 1176 | 1077 | 2 | 829 | 27 |
"ICD/CRT-D baseline programming measurements, detection interval. Implanted Cardioverter/Defibrillator paces a patient's heart in a tachyarrhythmia prevention-pacing mode.~Detection intervals are used to detect atrial tachyarrhythmia. Detection Intervals are programmable heart rate thresholds. R-R intervals that are less than the VT or VF detection intervals (in ms) are considered evidence of VT or VF, respectively. R-R intervals that are between the FVT and the VF detection intervals are considered evidence of FVT. Thus, these detection interval thresholds demarcate rate zones of detection. The rate zones are used to determine the type of therapy applied once detection occurs." (NCT00277524)
Timeframe: Baseline
| Intervention | ms (Mean) | ||||
|---|---|---|---|---|---|
| Pace AV | Sense AV | FVT Detection Interval | VF Detection Interval | VT Detection Interval | |
| ICD/CRT-D Group | 168 | 139 | 260 | 314 | 383 |
Pacing mode is based on the NASPE/BPEG Generic (NBG) Pacemake coding which includes: I, the chambers paced (V= Ventricle, A=Atrium, D=Dual (A&V), O=None); II, the chambers sensed (V= Ventricle, A=Atrium, D=Dual (A&V), O=None); III, the mode of response (T=Triggered, I=Inhibited, D=Dual Triggered/Inhibited, O=None); IV, the programmable functions(R=Rate Modulated, C=Communicating, M=Multiprogrammable, P=Simple Programmable, O=None); V, the antitachycardia functions (O=None, P=Paced, S=Shocks, D=Dual (P&S)). In addition, MVP (managed ventricular pacing) is a mode that promotes AV conduction by reducing or eliminating unnecessary RV pacing but maintains dual chamber ventricular support in the event that AV conduction is lost. (NCT00277524)
Timeframe: Baseline
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| Pacing Mode, DDD/DDDR | Pacing Mode, DDI/DDIR | Pacing Mode, MVP_AAIR_DD | Pacing Mode, MVP_AAI_DDD | Pacing Mode, VVI/VVIR | |
| IPG Group | 81 | 4 | 380 | 148 | 7 |
Frequencies of implanted systems were measured among patients who were implanted with a device (IPT, ICD or CRT-D). (NCT00277524)
Timeframe: Baseline
| Intervention | participants (Number) | |||||
|---|---|---|---|---|---|---|
| EnRhythm (P1501DR) | EnTrust AT (D154ATG) | EnTrust VR (D154VRC) | InSync Sentry (7297) | InSync Sentry (7299) | Intrinsic DR (7288) | |
| Implanted Subjects | 620 | 820 | 321 | 30 | 820 | 271 |
Evaluate the utility of the Antitachycardia Pacing (ATP) During Charging feature of the device. (NCT00277524)
Timeframe: 4 years post enrollment
| Intervention | Episodes (Number) | ||
|---|---|---|---|
| Number of episodes analyzed from 343 participants | Episodes with ATP attempted | Episodes with Sucessful ATP | |
| ATP During Charging | 1584 | 1100 | 650 |
Records participants hospitalized for VT during the study (NCT01576042)
Timeframe: Baseline, 6 months
| Intervention | participants (Number) |
|---|---|
| Catheter Ablation | 5 |
| Antiarrhythmic Medication | 7 |
Records participants who completed Month 3 Follow-Up Visit (NCT01576042)
Timeframe: 3 months
| Intervention | participants (Number) |
|---|---|
| Catheter Ablation | 11 |
| Antiarrhythmic Medication | 12 |
Records participants who completed Month 6 Follow-Up Visit (NCT01576042)
Timeframe: 6 Months
| Intervention | participants (Number) |
|---|---|
| Catheter Ablation | 7 |
| Antiarrhythmic Medication | 10 |
Records participants who had at least one of the efficacy outcome measurement (including death, hospitalization due to VT) (NCT01576042)
Timeframe: 6 Months
| Intervention | participants (Number) |
|---|---|
| Catheter Ablation | 11 |
| Antiarrhythmic Medication | 14 |
Records participants who received study randomized treatment during the study (NCT01576042)
Timeframe: 6 months
| Intervention | participants (Number) |
|---|---|
| Catheter Ablation | 11 |
| Antiarrhythmic Medication | 14 |
Records participants who only received study treatment as randomized during the entire study (NCT01576042)
Timeframe: 6 month
| Intervention | participants (Number) |
|---|---|
| Catheter Ablation | 6 |
| Antiarrhythmic Medication | 13 |
Records participants who received study treatment as randomized and later switched to other treatment arm during the study (NCT01576042)
Timeframe: 6 months
| Intervention | participants (Number) |
|---|---|
| Catheter Ablation | 5 |
| Antiarrhythmic Medication | 1 |
Days from the date of the first study treatment to the date of first ICD recurrent therapy for VT. (NCT01576042)
Timeframe: Baseline, 6 months
| Intervention | Days (Mean) |
|---|---|
| Catheter Ablation | 70.1 |
| Antiarrhythmic Medication | 78.7 |
(NCT00932659)
Timeframe: 6 months
| Intervention | participants (Number) |
|---|---|
| Single Arm: Hemodialysis Patients Implanted With REVEAL Device | 0 |
(NCT00932659)
Timeframe: 6 months
| Intervention | participants (Number) |
|---|---|
| Single Arm: Hemodialysis Patients Implanted With REVEAL Device | 0 |
80 reviews available for amiodarone and Death, Sudden, Cardiac
| Article | Year |
|---|---|
Amiodarone in ventricular arrhythmias: still a valuable resource?
Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Death, Sudden, Cardiac; Defibrillators, Im | 2021 |
Systematic Review and Meta-Analysis of Clinical Outcome After Implantable Cardioverter-Defibrillator Therapy in Patients With Chagas Heart Disease.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Chagas Cardiomyopathy; Death, Sudde | 2019 |
Quality of life in patients with implantable cardioverter-defibrillator: systematic review of randomized controlled trials.
Topics: Amiodarone; Anti-Arrhythmia Agents; Death, Sudden, Cardiac; Defibrillators, Implantable; Humans; Qua | 2018 |
Amiodarone versus other pharmacological interventions for prevention of sudden cardiac death.
Topics: Adult; Amiodarone; Anti-Arrhythmia Agents; Cause of Death; Death, Sudden, Cardiac; Humans; Primary P | 2015 |
Amiodarone for the prevention of sudden cardiac death: a meta-analysis of randomized controlled trials.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cause of Death; Death, Sudden, Cardiac; Female; Humans; Ma | 2009 |
Appropriate evaluation and treatment of heart failure patients after implantable cardioverter-defibrillator discharge: time to go beyond the initial shock.
Topics: Adrenergic beta-Antagonists; Algorithms; Amiodarone; Anti-Arrhythmia Agents; Death, Sudden, Cardiac; | 2009 |
Ventricular tachyarrhythmias (out-of-hospital cardiac arrests).
Topics: Amiodarone; Death, Sudden, Cardiac; Electric Countershock; Humans; Hypothermia, Induced; Lidocaine; | 2010 |
Role of antiarrhythmic drugs: frequent implantable cardioverter-defibrillator shocks, risk of proarrhythmia, and new drug therapy.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Cardiomyopathies; Death, Sudden, Ca | 2011 |
Amiodarone supplants lidocaine in ACLS and CPR protocols.
Topics: Action Potentials; Advanced Cardiac Life Support; Amiodarone; Anti-Arrhythmia Agents; Bretylium Comp | 2011 |
Examining the safety of amiodarone.
Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Death, Sudden, Cardiac; Evidence-Based Med | 2012 |
[Incessant or recurrent ventricular tachycardia. Indications for emergency ablation].
Topics: Amiodarone; Anti-Arrhythmia Agents; Catheter Ablation; Combined Modality Therapy; Contraindications; | 2012 |
[Heart failure].
Topics: Adrenergic beta-Antagonists; Amiodarone; Angiotensin Receptor Antagonists; Angiotensin-Converting En | 2002 |
[Arrhythmias in cardiomyopathies].
Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cardiomyopathies; Death, Sudden, Cardiac; | 2002 |
Significance and control of cardiac arrhythmias in patients with congestive cardiac failure.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Death, Sudden, | 2002 |
Overview of randomized trials of antiarrhythmic drugs and devices for the prevention of sudden cardiac death.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Death, Sudden, Cardiac; Defibrillators, Implantable; Femal | 2002 |
[Drug therapy of ventricular arrhythmias - a contemporary perspective].
Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Calcium Channel Blockers; Clinical Trials | 2002 |
Sudden cardiac death in dilated cardiomyopathy -- therapeutic options.
Topics: Adrenergic beta-Antagonists; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Cardiomyopathy, D | 2002 |
Antiarrhythmic therapy in heart failure.
Topics: Algorithms; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhythmia Agents; Arrhythmia | 2002 |
Better living through chemistry: does it still apply to patients after myocardial infarction?
Topics: Adrenergic beta-Antagonists; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Cardiovascular Ag | 2003 |
Role of amiodarone in the era of the implantable cardioverter defibrillator.
Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Clinical Trials as Topic; Combined Modalit | 2003 |
Clinical inquiries. Do antiarrhythmics prevent sudden death in patients with heart failure?
Topics: Amiodarone; Anti-Arrhythmia Agents; Death, Sudden, Cardiac; Evidence-Based Medicine; Heart Failure; | 2003 |
Management of hypertrophic cardiomyopathy in children.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Calcium Chann | 2003 |
Sudden cardiac death: prevention and treatment.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Contraindicat | 2003 |
Are implantable cardioverter-defribrillators always superior to amiodarone?
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cardiomyopathy, Dilated; Cost-Benefi | 2003 |
Sudden death and hypertrophic cardiomyopathy: a review.
Topics: Amiodarone; Anti-Arrhythmia Agents; Cardiomyopathy, Hypertrophic; Death, Sudden, Cardiac; Defibrilla | 2005 |
A review of carvedilol arrhythmia data in clinical trials.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Bisoprolol; Ca | 2005 |
Can amiodarone prevent sudden cardiac death in patients with hemodynamically tolerated sustained ventricular tachycardia and coronary artery disease?
Topics: Amiodarone; Clinical Trials as Topic; Coronary Disease; Death, Sudden, Cardiac; Defibrillators, Impl | 2005 |
[Clinical therapy for arrhythmias and EBM].
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Arrhythmias, Cardia | 2006 |
[Lethal arrhythmia associated with heart failure].
Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Death, Sudden, Cardiac; Defibrillators, Im | 2007 |
[Antiarrhythmic drug therapy in patients with heart failure].
Topics: Adrenergic beta-Antagonists; Amiodarone; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Conver | 2007 |
Empiric long-term amiodarone prophylaxis following myocardial infarction. A meta-analysis.
Topics: Aged; Amiodarone; Cardiac Complexes, Premature; Death, Sudden, Cardiac; Female; Humans; Male; Middle | 1993 |
[Sudden death in hypertrophic myocardiopathy].
Topics: Amiodarone; Cardiomyopathy, Hypertrophic; Death, Sudden, Cardiac; Heart; Humans; Risk Factors | 1995 |
Amiodarone and post-MI patients.
Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Coronary Disease; Death, Sudden, Cardiac; | 1993 |
Hypertrophic cardiomyopathy.
Topics: Adolescent; Adult; Age Factors; Aged; Amiodarone; Cardiac Pacing, Artificial; Cardiomyopathy, Hypert | 1993 |
[Management of patients with risk of sudden death. The amiodarone example].
Topics: Amiodarone; Arrhythmias, Cardiac; Canada; Cardiomyopathy, Dilated; Death, Sudden, Cardiac; Europe; H | 1994 |
[Congestive heart failure and arrhythmia].
Topics: Adrenergic beta-Antagonists; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhythmia A | 1993 |
Pharmacological therapy in coronary heart disease: prevention of life-threatening ventricular tachyarrhythmias and sudden cardiac death.
Topics: Action Potentials; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhythmia Agents; Cal | 1993 |
Empiric use of amiodarone and sotalol.
Topics: Amiodarone; Cardiomyopathy, Hypertrophic; Coronary Disease; Death, Sudden, Cardiac; Heart Diseases; | 1993 |
Secondary prevention after myocardial infarction with class III antiarrhythmic drugs.
Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Clinical Trials as Topic; Death, Sudden, C | 1993 |
Sudden death prevention in patients with advanced ventricular dysfunction.
Topics: Adult; Aged; Aged, 80 and over; Amiodarone; Arrhythmias, Cardiac; Cardiomyopathy, Dilated; Death, Su | 1993 |
Concomitant amiodarone and the implantable cardioverter-defibrillator: is there a place?
Topics: Amiodarone; Animals; Combined Modality Therapy; Death, Sudden, Cardiac; Defibrillators, Implantable; | 1993 |
Right bundle branch block, persistent ST-segment elevation in V1-V3 and sudden cardiac death: always a distinct syndrome?
Topics: Adult; Amiodarone; Bundle-Branch Block; Death, Sudden, Cardiac; Echocardiography; Electrocardiograph | 1995 |
Should post-infarction asymptomatic ventricular arrhythmias be treated? The need for caution.
Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Death, Sudden, Cardiac; Heart Ventricles; | 1995 |
Expanding indications for the use of Class III agents in patients at high risk for sudden death.
Topics: Amiodarone; Anti-Arrhythmia Agents; Clinical Trials as Topic; Death, Sudden, Cardiac; Humans; Risk F | 1995 |
[Anti-arrhythmic therapy and cardiac failure].
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Death, Sudden | 1995 |
Risk assessment and prevention of sudden cardiac death in hypertrophic cardiomyopathy.
Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cardiac Pacing, Artificial; Cardiomyopathy | 1996 |
[Prognostic factors after sustained ventricular fibrillation or tachycardia. A multivariate study apropos of 160 cases].
Topics: Actuarial Analysis; Adrenergic beta-Antagonists; Adult; Age Factors; Aged; Amiodarone; Cardiac Pacin | 1996 |
[Arrhythmias with normal heart rate].
Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Premature Complexes; Death, Sudden, | 1996 |
Major clinical trials assessing the prophylactic use of amiodarone in patients with ventricular tachyarrhythmias.
Topics: Amiodarone; Anti-Arrhythmia Agents; Death, Sudden, Cardiac; Defibrillators, Implantable; Humans; Myo | 1996 |
[Anti-arrhythmia therapy after myocardial infarct: preliminary results of EMIAT and CAMIAT studies].
Topics: Adult; Aged; Amiodarone; Death, Sudden, Cardiac; Electrocardiography, Ambulatory; Female; Heart Cond | 1996 |
[Pharmacologic therapy of ventricular tachyarrhythmias: value of class III anti-arrhythmia drugs].
Topics: Amiodarone; Anti-Arrhythmia Agents; Clinical Trials as Topic; Combined Modality Therapy; Death, Sudd | 1996 |
Antiarrhythmic therapies for the prevention of sudden cardiac death.
Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Coronary Artery Bypass; Death, Sudden, Car | 1997 |
What can we expect from prophylactic implantable defibrillators?
Topics: Amiodarone; Anti-Arrhythmia Agents; Cause of Death; Death, Sudden, Cardiac; Defibrillators, Implanta | 1997 |
Effect of prophylactic amiodarone on mortality after acute myocardial infarction and in congestive heart failure: meta-analysis of individual data from 6500 patients in randomised trials. Amiodarone Trials Meta-Analysis Investigators.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Death, Sudden, Cardiac; Female; Hear | 1997 |
The place of amiodarone: an overview of the four recent large controlled trials.
Topics: Amiodarone; Anti-Arrhythmia Agents; Controlled Clinical Trials as Topic; Death, Sudden, Cardiac; Hea | 1997 |
Unexpected instant death following successful coronary artery bypass graft surgery (and other clinical settings): atrial fibrillation, quinidine, procainamide, et cetera, and instant death.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Clinical Trials as Topic; Coronary Artery B | 1998 |
Amiodarone in congestive heart failure.
Topics: Amiodarone; Anti-Arrhythmia Agents; Clinical Trials as Topic; Death, Sudden, Cardiac; Heart Failure; | 1998 |
Prevention of sudden cardiac death: a current perspective.
Topics: Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; | 1998 |
Amiodarone and "primary" prevention of sudden death: critical review of a decade of clinical trials.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Clinical Trials as Topic; Death, Sudden, Cardiac; Female; | 1999 |
Antiarrhythmic drugs or implantable cardioverter defibrillators in heart failure: the "poor heart".
Topics: Amiodarone; Anti-Arrhythmia Agents; Death, Sudden, Cardiac; Defibrillators, Implantable; Heart Failu | 1999 |
New primary prevention trials of sudden cardiac death in patients with left ventricular dysfunction: SCD-HEFT and MADIT-II.
Topics: Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Death, Sudden, Cardiac; Defibrillators, Implantable | 1999 |
Sudden cardiac death prevention: antiarrhythmic drugs and the implantable cardioverter-defibrillator.
Topics: Actuarial Analysis; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Combined Modality Ther | 1995 |
Sudden cardiac death: who needs an implantable cardioverter-defibrillator and who needs antiarrhythmic drugs?
Topics: Amiodarone; Anti-Arrhythmia Agents; Death, Sudden, Cardiac; Defibrillators, Implantable; Humans; Sec | 1999 |
Implantable defibrillators and antiarrhythmic drugs in patients at risk for lethal arrhythmias.
Topics: Amiodarone; Anti-Arrhythmia Agents; Clinical Trials as Topic; Death, Sudden, Cardiac; Defibrillators | 1999 |
Class III drugs and congestive heart failure: focus on the congestive heart failure-survival trial of antiarrhythmic therapy.
Topics: Amiodarone; Anti-Arrhythmia Agents; Clinical Trials as Topic; Death, Sudden, Cardiac; Heart Failure; | 1999 |
Arrhythmic risk stratification of post-myocardial infarction patients.
Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Death, Sudden, Cardiac; Electrophysiology; | 2000 |
Amiodarone: what have we learned from clinical trials?
Topics: Amiodarone; Anti-Arrhythmia Agents; Clinical Trials as Topic; Death, Sudden, Cardiac; Defibrillators | 2000 |
Combination ICD and drug treatments-best options.
Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Combined Modality Therapy; Death, Sudden, | 2000 |
Evidence-based medicine and the implantable defibrillator.
Topics: Amiodarone; Anti-Arrhythmia Agents; Coronary Artery Bypass; Death, Sudden, Cardiac; Defibrillators, | 1999 |
Is primary antiarrhythmic drug therapy for ventricular arrhythmias obsolete?
Topics: Amiodarone; Anti-Arrhythmia Agents; Death, Sudden, Cardiac; Defibrillators, Implantable; Humans; Ran | 1999 |
Beta-blockers and amiodarone for the primary prevention of sudden cardiac death.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Death, Sudden, Cardiac; Heart Failu | 1999 |
Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials. AVID, CASH and CIDS studies. Antiarrhythmics vs Implantable Defibrillator study. Cardiac Arrest Study Hamburg . Canadian Implantable Defibrillator Study.
Topics: Amiodarone; Anti-Arrhythmia Agents; Death, Sudden, Cardiac; Defibrillators, Implantable; Humans; Ran | 2000 |
Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials. AVID, CASH and CIDS studies. Antiarrhythmics vs Implantable Defibrillator study. Cardiac Arrest Study Hamburg . Canadian Implantable Defibrillator Study.
Topics: Amiodarone; Anti-Arrhythmia Agents; Death, Sudden, Cardiac; Defibrillators, Implantable; Humans; Ran | 2000 |
Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials. AVID, CASH and CIDS studies. Antiarrhythmics vs Implantable Defibrillator study. Cardiac Arrest Study Hamburg . Canadian Implantable Defibrillator Study.
Topics: Amiodarone; Anti-Arrhythmia Agents; Death, Sudden, Cardiac; Defibrillators, Implantable; Humans; Ran | 2000 |
Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials. AVID, CASH and CIDS studies. Antiarrhythmics vs Implantable Defibrillator study. Cardiac Arrest Study Hamburg . Canadian Implantable Defibrillator Study.
Topics: Amiodarone; Anti-Arrhythmia Agents; Death, Sudden, Cardiac; Defibrillators, Implantable; Humans; Ran | 2000 |
Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials. AVID, CASH and CIDS studies. Antiarrhythmics vs Implantable Defibrillator study. Cardiac Arrest Study Hamburg . Canadian Implantable Defibrillator Study.
Topics: Amiodarone; Anti-Arrhythmia Agents; Death, Sudden, Cardiac; Defibrillators, Implantable; Humans; Ran | 2000 |
Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials. AVID, CASH and CIDS studies. Antiarrhythmics vs Implantable Defibrillator study. Cardiac Arrest Study Hamburg . Canadian Implantable Defibrillator Study.
Topics: Amiodarone; Anti-Arrhythmia Agents; Death, Sudden, Cardiac; Defibrillators, Implantable; Humans; Ran | 2000 |
Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials. AVID, CASH and CIDS studies. Antiarrhythmics vs Implantable Defibrillator study. Cardiac Arrest Study Hamburg . Canadian Implantable Defibrillator Study.
Topics: Amiodarone; Anti-Arrhythmia Agents; Death, Sudden, Cardiac; Defibrillators, Implantable; Humans; Ran | 2000 |
Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials. AVID, CASH and CIDS studies. Antiarrhythmics vs Implantable Defibrillator study. Cardiac Arrest Study Hamburg . Canadian Implantable Defibrillator Study.
Topics: Amiodarone; Anti-Arrhythmia Agents; Death, Sudden, Cardiac; Defibrillators, Implantable; Humans; Ran | 2000 |
Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials. AVID, CASH and CIDS studies. Antiarrhythmics vs Implantable Defibrillator study. Cardiac Arrest Study Hamburg . Canadian Implantable Defibrillator Study.
Topics: Amiodarone; Anti-Arrhythmia Agents; Death, Sudden, Cardiac; Defibrillators, Implantable; Humans; Ran | 2000 |
Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials. AVID, CASH and CIDS studies. Antiarrhythmics vs Implantable Defibrillator study. Cardiac Arrest Study Hamburg . Canadian Implantable Defibrillator Study.
Topics: Amiodarone; Anti-Arrhythmia Agents; Death, Sudden, Cardiac; Defibrillators, Implantable; Humans; Ran | 2000 |
Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials. AVID, CASH and CIDS studies. Antiarrhythmics vs Implantable Defibrillator study. Cardiac Arrest Study Hamburg . Canadian Implantable Defibrillator Study.
Topics: Amiodarone; Anti-Arrhythmia Agents; Death, Sudden, Cardiac; Defibrillators, Implantable; Humans; Ran | 2000 |
Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials. AVID, CASH and CIDS studies. Antiarrhythmics vs Implantable Defibrillator study. Cardiac Arrest Study Hamburg . Canadian Implantable Defibrillator Study.
Topics: Amiodarone; Anti-Arrhythmia Agents; Death, Sudden, Cardiac; Defibrillators, Implantable; Humans; Ran | 2000 |
Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials. AVID, CASH and CIDS studies. Antiarrhythmics vs Implantable Defibrillator study. Cardiac Arrest Study Hamburg . Canadian Implantable Defibrillator Study.
Topics: Amiodarone; Anti-Arrhythmia Agents; Death, Sudden, Cardiac; Defibrillators, Implantable; Humans; Ran | 2000 |
Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials. AVID, CASH and CIDS studies. Antiarrhythmics vs Implantable Defibrillator study. Cardiac Arrest Study Hamburg . Canadian Implantable Defibrillator Study.
Topics: Amiodarone; Anti-Arrhythmia Agents; Death, Sudden, Cardiac; Defibrillators, Implantable; Humans; Ran | 2000 |
Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials. AVID, CASH and CIDS studies. Antiarrhythmics vs Implantable Defibrillator study. Cardiac Arrest Study Hamburg . Canadian Implantable Defibrillator Study.
Topics: Amiodarone; Anti-Arrhythmia Agents; Death, Sudden, Cardiac; Defibrillators, Implantable; Humans; Ran | 2000 |
Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials. AVID, CASH and CIDS studies. Antiarrhythmics vs Implantable Defibrillator study. Cardiac Arrest Study Hamburg . Canadian Implantable Defibrillator Study.
Topics: Amiodarone; Anti-Arrhythmia Agents; Death, Sudden, Cardiac; Defibrillators, Implantable; Humans; Ran | 2000 |
Perspectives: does amiodarone increase non-sudden deaths? If so, why?
Topics: Amiodarone; Anti-Arrhythmia Agents; Death, Sudden; Death, Sudden, Cardiac; Female; Heart Failure; Hu | 2000 |
[Clinical trials on heart failure].
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Amiodarone; Angiotensin-Converting Enzyme | 2001 |
Sudden death due to cardiac arrhythmias.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Baroreflex; C | 2001 |
Sudden death due to cardiac arrhythmias.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Baroreflex; C | 2001 |
Sudden death due to cardiac arrhythmias.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Baroreflex; C | 2001 |
Sudden death due to cardiac arrhythmias.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Baroreflex; C | 2001 |
[Arrhythmia risk stratification in patients with heart failure according to drug treatment and its effects].
Topics: Adrenergic beta-Antagonists; Amiodarone; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; A | 2001 |
Primary prevention in chronic ischemic heart disease.
Topics: Amiodarone; Anti-Arrhythmia Agents; Chronic Disease; Death, Sudden, Cardiac; Defibrillators, Implant | 2002 |
[What is the latest in anti-arrhythmia therapy?].
Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cardiac Complexes, Premature; Clinical Tri | 1991 |
Ventricular arrhythmias associated with congestive heart failure: the role for amiodarone.
Topics: Amiodarone; Arrhythmias, Cardiac; Death, Sudden, Cardiac; Heart Failure; Heart Ventricles; Humans | 1991 |
[Does amiodarone have a benefit effect on mortality?].
Topics: Amiodarone; Arrhythmias, Cardiac; Death, Sudden, Cardiac; Eye Diseases; France; Heart Arrest; Humans | 1991 |
54 trials available for amiodarone and Death, Sudden, Cardiac
| Article | Year |
|---|---|
Assessment of Comorbidity Burden and Treatment Response: Reanalysis of the SCD-HEFT Trial.
Topics: Amiodarone; Comorbidity; Death, Sudden, Cardiac; Defibrillators, Implantable; Heart Failure; Humans; | 2022 |
Long-Term Outcomes of Implantable Cardioverter-Defibrillator Therapy in the SCD-HeFT.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Death, Sudden, Cardiac; Defibrillators, Implantable; Elect | 2020 |
Efficacy of an implantable cardioverter-defibrillator in patients with diabetes and heart failure and reduced ejection fraction.
Topics: Aged; Amiodarone; Cause of Death; Death, Sudden, Cardiac; Defibrillators, Implantable; Diabetes Mell | 2019 |
CHronic use of Amiodarone aGAinSt Implantable cardioverter-defibrillator therapy for primary prevention of death in patients with Chagas cardiomyopathy Study: rationale and design of a randomized clinical trial.
Topics: Adolescent; Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Brazil; Chagas Cardiomyopathy; Death, S | 2013 |
Use of the 6-min walk distance to identify variations in treatment benefits from implantable cardioverter-defibrillator and amiodarone: results from the SCD-HeFT (Sudden Cardiac Death in Heart Failure Trial).
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Combined Modality Therapy; Death, Sudden, Cardiac; Defibri | 2014 |
Use of the 6-min walk distance to identify variations in treatment benefits from implantable cardioverter-defibrillator and amiodarone: results from the SCD-HeFT (Sudden Cardiac Death in Heart Failure Trial).
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Combined Modality Therapy; Death, Sudden, Cardiac; Defibri | 2014 |
Use of the 6-min walk distance to identify variations in treatment benefits from implantable cardioverter-defibrillator and amiodarone: results from the SCD-HeFT (Sudden Cardiac Death in Heart Failure Trial).
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Combined Modality Therapy; Death, Sudden, Cardiac; Defibri | 2014 |
Use of the 6-min walk distance to identify variations in treatment benefits from implantable cardioverter-defibrillator and amiodarone: results from the SCD-HeFT (Sudden Cardiac Death in Heart Failure Trial).
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Combined Modality Therapy; Death, Sudden, Cardiac; Defibri | 2014 |
Efficacy of amiodarone in patients with atrial fibrillation with and without left ventricular dysfunction: a pooled analysis of AFFIRM and AF-CHF trials.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Death, Sudden, Cardiac; Female; Hospi | 2014 |
SCD-HeFT: Use of R-R interval statistics for long-term risk stratification for arrhythmic sudden cardiac death.
Topics: Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Death, Sud | 2015 |
No benefit from defibrillation threshold testing in the SCD-HeFT (Sudden Cardiac Death in Heart Failure Trial).
Topics: Amiodarone; Anti-Arrhythmia Agents; Death, Sudden, Cardiac; Defibrillators, Implantable; Differentia | 2008 |
Ejection fraction assessment and survival: an analysis of the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT).
Topics: Aged; Amiodarone; Angiography; Anti-Arrhythmia Agents; Death, Sudden, Cardiac; Defibrillators, Impla | 2008 |
Prognostic factors affecting the all-cause death and sudden cardiac death rates of post myocardial infarction patients with low left ventricular ejection fraction.
Topics: Aged; Amiodarone; Angioplasty, Balloon; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhythmia Ag | 2009 |
Maximizing survival benefit with primary prevention implantable cardioverter-defibrillator therapy in a heart failure population.
Topics: Adult; Amiodarone; Anti-Arrhythmia Agents; Death, Sudden, Cardiac; Defibrillators, Implantable; Fema | 2009 |
Impact of implantable cardioverter-defibrillator, amiodarone, and placebo on the mode of death in stable patients with heart failure: analysis from the sudden cardiac death in heart failure trial.
Topics: Amiodarone; Anti-Arrhythmia Agents; Cause of Death; Combined Modality Therapy; Death, Sudden, Cardia | 2009 |
Impact of implantable cardioverter-defibrillator, amiodarone, and placebo on the mode of death in stable patients with heart failure: analysis from the sudden cardiac death in heart failure trial.
Topics: Amiodarone; Anti-Arrhythmia Agents; Cause of Death; Combined Modality Therapy; Death, Sudden, Cardia | 2009 |
Impact of implantable cardioverter-defibrillator, amiodarone, and placebo on the mode of death in stable patients with heart failure: analysis from the sudden cardiac death in heart failure trial.
Topics: Amiodarone; Anti-Arrhythmia Agents; Cause of Death; Combined Modality Therapy; Death, Sudden, Cardia | 2009 |
Impact of implantable cardioverter-defibrillator, amiodarone, and placebo on the mode of death in stable patients with heart failure: analysis from the sudden cardiac death in heart failure trial.
Topics: Amiodarone; Anti-Arrhythmia Agents; Cause of Death; Combined Modality Therapy; Death, Sudden, Cardia | 2009 |
Impact of implantable cardioverter-defibrillator, amiodarone, and placebo on the mode of death in stable patients with heart failure: analysis from the sudden cardiac death in heart failure trial.
Topics: Amiodarone; Anti-Arrhythmia Agents; Cause of Death; Combined Modality Therapy; Death, Sudden, Cardia | 2009 |
Impact of implantable cardioverter-defibrillator, amiodarone, and placebo on the mode of death in stable patients with heart failure: analysis from the sudden cardiac death in heart failure trial.
Topics: Amiodarone; Anti-Arrhythmia Agents; Cause of Death; Combined Modality Therapy; Death, Sudden, Cardia | 2009 |
Impact of implantable cardioverter-defibrillator, amiodarone, and placebo on the mode of death in stable patients with heart failure: analysis from the sudden cardiac death in heart failure trial.
Topics: Amiodarone; Anti-Arrhythmia Agents; Cause of Death; Combined Modality Therapy; Death, Sudden, Cardia | 2009 |
Impact of implantable cardioverter-defibrillator, amiodarone, and placebo on the mode of death in stable patients with heart failure: analysis from the sudden cardiac death in heart failure trial.
Topics: Amiodarone; Anti-Arrhythmia Agents; Cause of Death; Combined Modality Therapy; Death, Sudden, Cardia | 2009 |
Impact of implantable cardioverter-defibrillator, amiodarone, and placebo on the mode of death in stable patients with heart failure: analysis from the sudden cardiac death in heart failure trial.
Topics: Amiodarone; Anti-Arrhythmia Agents; Cause of Death; Combined Modality Therapy; Death, Sudden, Cardia | 2009 |
Efficacy and safety of celivarone, with amiodarone as calibrator, in patients with an implantable cardioverter-defibrillator for prevention of implantable cardioverter-defibrillator interventions or death: the ALPHEE study.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Benzofurans; Death, Sudden, Cardiac; Defibrillators, Impla | 2011 |
Are implantable cardioverter-defribrillators always superior to amiodarone?
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cardiomyopathy, Dilated; Cost-Benefi | 2003 |
The Midlands Trial of Empirical Amiodarone versus Electrophysiology-guided Interventions and Implantable Cardioverter-defibrillators (MAVERIC): a multi-centre prospective randomised clinical trial on the secondary prevention of sudden cardiac death.
Topics: Amiodarone; Anti-Arrhythmia Agents; Clinical Protocols; Death, Sudden, Cardiac; Defibrillators, Impl | 2004 |
Long-term comparison of the implantable cardioverter defibrillator versus amiodarone: eleven-year follow-up of a subset of patients in the Canadian Implantable Defibrillator Study (CIDS).
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Canada; Comorbidity; Coronary Artery Bypass; Death, Sudden | 2004 |
Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cause of Death; Cross-Over Studies; Death, Sudden, Cardiac | 2005 |
Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cause of Death; Cross-Over Studies; Death, Sudden, Cardiac | 2005 |
Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cause of Death; Cross-Over Studies; Death, Sudden, Cardiac | 2005 |
Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cause of Death; Cross-Over Studies; Death, Sudden, Cardiac | 2005 |
Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cause of Death; Cross-Over Studies; Death, Sudden, Cardiac | 2005 |
Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cause of Death; Cross-Over Studies; Death, Sudden, Cardiac | 2005 |
Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cause of Death; Cross-Over Studies; Death, Sudden, Cardiac | 2005 |
Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cause of Death; Cross-Over Studies; Death, Sudden, Cardiac | 2005 |
Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cause of Death; Cross-Over Studies; Death, Sudden, Cardiac | 2005 |
Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cause of Death; Cross-Over Studies; Death, Sudden, Cardiac | 2005 |
Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cause of Death; Cross-Over Studies; Death, Sudden, Cardiac | 2005 |
Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cause of Death; Cross-Over Studies; Death, Sudden, Cardiac | 2005 |
Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cause of Death; Cross-Over Studies; Death, Sudden, Cardiac | 2005 |
Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cause of Death; Cross-Over Studies; Death, Sudden, Cardiac | 2005 |
Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cause of Death; Cross-Over Studies; Death, Sudden, Cardiac | 2005 |
Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cause of Death; Cross-Over Studies; Death, Sudden, Cardiac | 2005 |
Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cause of Death; Cross-Over Studies; Death, Sudden, Cardiac | 2005 |
Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cause of Death; Cross-Over Studies; Death, Sudden, Cardiac | 2005 |
Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cause of Death; Cross-Over Studies; Death, Sudden, Cardiac | 2005 |
Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cause of Death; Cross-Over Studies; Death, Sudden, Cardiac | 2005 |
Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cause of Death; Cross-Over Studies; Death, Sudden, Cardiac | 2005 |
Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cause of Death; Cross-Over Studies; Death, Sudden, Cardiac | 2005 |
Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cause of Death; Cross-Over Studies; Death, Sudden, Cardiac | 2005 |
Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cause of Death; Cross-Over Studies; Death, Sudden, Cardiac | 2005 |
Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cause of Death; Cross-Over Studies; Death, Sudden, Cardiac | 2005 |
Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cause of Death; Cross-Over Studies; Death, Sudden, Cardiac | 2005 |
Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cause of Death; Cross-Over Studies; Death, Sudden, Cardiac | 2005 |
Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cause of Death; Cross-Over Studies; Death, Sudden, Cardiac | 2005 |
Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cause of Death; Cross-Over Studies; Death, Sudden, Cardiac | 2005 |
Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cause of Death; Cross-Over Studies; Death, Sudden, Cardiac | 2005 |
Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cause of Death; Cross-Over Studies; Death, Sudden, Cardiac | 2005 |
Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cause of Death; Cross-Over Studies; Death, Sudden, Cardiac | 2005 |
Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cause of Death; Cross-Over Studies; Death, Sudden, Cardiac | 2005 |
Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cause of Death; Cross-Over Studies; Death, Sudden, Cardiac | 2005 |
Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cause of Death; Cross-Over Studies; Death, Sudden, Cardiac | 2005 |
Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cause of Death; Cross-Over Studies; Death, Sudden, Cardiac | 2005 |
Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cause of Death; Cross-Over Studies; Death, Sudden, Cardiac | 2005 |
Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cause of Death; Cross-Over Studies; Death, Sudden, Cardiac | 2005 |
Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cause of Death; Cross-Over Studies; Death, Sudden, Cardiac | 2005 |
Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cause of Death; Cross-Over Studies; Death, Sudden, Cardiac | 2005 |
Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cause of Death; Cross-Over Studies; Death, Sudden, Cardiac | 2005 |
Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cause of Death; Cross-Over Studies; Death, Sudden, Cardiac | 2005 |
Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cause of Death; Cross-Over Studies; Death, Sudden, Cardiac | 2005 |
Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cause of Death; Cross-Over Studies; Death, Sudden, Cardiac | 2005 |
Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cause of Death; Cross-Over Studies; Death, Sudden, Cardiac | 2005 |
Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cause of Death; Cross-Over Studies; Death, Sudden, Cardiac | 2005 |
Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cause of Death; Cross-Over Studies; Death, Sudden, Cardiac | 2005 |
Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cause of Death; Cross-Over Studies; Death, Sudden, Cardiac | 2005 |
Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cause of Death; Cross-Over Studies; Death, Sudden, Cardiac | 2005 |
Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cause of Death; Cross-Over Studies; Death, Sudden, Cardiac | 2005 |
Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cause of Death; Cross-Over Studies; Death, Sudden, Cardiac | 2005 |
Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cause of Death; Cross-Over Studies; Death, Sudden, Cardiac | 2005 |
Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cause of Death; Cross-Over Studies; Death, Sudden, Cardiac | 2005 |
Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cause of Death; Cross-Over Studies; Death, Sudden, Cardiac | 2005 |
Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cause of Death; Cross-Over Studies; Death, Sudden, Cardiac | 2005 |
Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cause of Death; Cross-Over Studies; Death, Sudden, Cardiac | 2005 |
Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cause of Death; Cross-Over Studies; Death, Sudden, Cardiac | 2005 |
Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cause of Death; Cross-Over Studies; Death, Sudden, Cardiac | 2005 |
Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cause of Death; Cross-Over Studies; Death, Sudden, Cardiac | 2005 |
Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cause of Death; Cross-Over Studies; Death, Sudden, Cardiac | 2005 |
Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cause of Death; Cross-Over Studies; Death, Sudden, Cardiac | 2005 |
Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cause of Death; Cross-Over Studies; Death, Sudden, Cardiac | 2005 |
Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cause of Death; Cross-Over Studies; Death, Sudden, Cardiac | 2005 |
Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cause of Death; Cross-Over Studies; Death, Sudden, Cardiac | 2005 |
Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cause of Death; Cross-Over Studies; Death, Sudden, Cardiac | 2005 |
Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cause of Death; Cross-Over Studies; Death, Sudden, Cardiac | 2005 |
Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cause of Death; Cross-Over Studies; Death, Sudden, Cardiac | 2005 |
Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cause of Death; Cross-Over Studies; Death, Sudden, Cardiac | 2005 |
Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cause of Death; Cross-Over Studies; Death, Sudden, Cardiac | 2005 |
Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cause of Death; Cross-Over Studies; Death, Sudden, Cardiac | 2005 |
Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cause of Death; Cross-Over Studies; Death, Sudden, Cardiac | 2005 |
Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cause of Death; Cross-Over Studies; Death, Sudden, Cardiac | 2005 |
Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cause of Death; Cross-Over Studies; Death, Sudden, Cardiac | 2005 |
Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cause of Death; Cross-Over Studies; Death, Sudden, Cardiac | 2005 |
Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cause of Death; Cross-Over Studies; Death, Sudden, Cardiac | 2005 |
Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cause of Death; Cross-Over Studies; Death, Sudden, Cardiac | 2005 |
Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cause of Death; Cross-Over Studies; Death, Sudden, Cardiac | 2005 |
Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cause of Death; Cross-Over Studies; Death, Sudden, Cardiac | 2005 |
Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cause of Death; Cross-Over Studies; Death, Sudden, Cardiac | 2005 |
Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cause of Death; Cross-Over Studies; Death, Sudden, Cardiac | 2005 |
Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cause of Death; Cross-Over Studies; Death, Sudden, Cardiac | 2005 |
Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cause of Death; Cross-Over Studies; Death, Sudden, Cardiac | 2005 |
Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cause of Death; Cross-Over Studies; Death, Sudden, Cardiac | 2005 |
Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cause of Death; Cross-Over Studies; Death, Sudden, Cardiac | 2005 |
Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cause of Death; Cross-Over Studies; Death, Sudden, Cardiac | 2005 |
Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cause of Death; Cross-Over Studies; Death, Sudden, Cardiac | 2005 |
Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cause of Death; Cross-Over Studies; Death, Sudden, Cardiac | 2005 |
Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cause of Death; Cross-Over Studies; Death, Sudden, Cardiac | 2005 |
Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cause of Death; Cross-Over Studies; Death, Sudden, Cardiac | 2005 |
Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cause of Death; Cross-Over Studies; Death, Sudden, Cardiac | 2005 |
Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cause of Death; Cross-Over Studies; Death, Sudden, Cardiac | 2005 |
Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cause of Death; Cross-Over Studies; Death, Sudden, Cardiac | 2005 |
Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cause of Death; Cross-Over Studies; Death, Sudden, Cardiac | 2005 |
Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cause of Death; Cross-Over Studies; Death, Sudden, Cardiac | 2005 |
Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cause of Death; Cross-Over Studies; Death, Sudden, Cardiac | 2005 |
Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cause of Death; Cross-Over Studies; Death, Sudden, Cardiac | 2005 |
Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cause of Death; Cross-Over Studies; Death, Sudden, Cardiac | 2005 |
Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cause of Death; Cross-Over Studies; Death, Sudden, Cardiac | 2005 |
Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cause of Death; Cross-Over Studies; Death, Sudden, Cardiac | 2005 |
Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cause of Death; Cross-Over Studies; Death, Sudden, Cardiac | 2005 |
Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cause of Death; Cross-Over Studies; Death, Sudden, Cardiac | 2005 |
Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cause of Death; Cross-Over Studies; Death, Sudden, Cardiac | 2005 |
Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cause of Death; Cross-Over Studies; Death, Sudden, Cardiac | 2005 |
Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cause of Death; Cross-Over Studies; Death, Sudden, Cardiac | 2005 |
Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cause of Death; Cross-Over Studies; Death, Sudden, Cardiac | 2005 |
Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cause of Death; Cross-Over Studies; Death, Sudden, Cardiac | 2005 |
Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cause of Death; Cross-Over Studies; Death, Sudden, Cardiac | 2005 |
Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cause of Death; Cross-Over Studies; Death, Sudden, Cardiac | 2005 |
Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cause of Death; Cross-Over Studies; Death, Sudden, Cardiac | 2005 |
Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cause of Death; Cross-Over Studies; Death, Sudden, Cardiac | 2005 |
Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cause of Death; Cross-Over Studies; Death, Sudden, Cardiac | 2005 |
Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cause of Death; Cross-Over Studies; Death, Sudden, Cardiac | 2005 |
Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cause of Death; Cross-Over Studies; Death, Sudden, Cardiac | 2005 |
Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cause of Death; Cross-Over Studies; Death, Sudden, Cardiac | 2005 |
Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cause of Death; Cross-Over Studies; Death, Sudden, Cardiac | 2005 |
Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cause of Death; Cross-Over Studies; Death, Sudden, Cardiac | 2005 |
Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cause of Death; Cross-Over Studies; Death, Sudden, Cardiac | 2005 |
Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cause of Death; Cross-Over Studies; Death, Sudden, Cardiac | 2005 |
Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cause of Death; Cross-Over Studies; Death, Sudden, Cardiac | 2005 |
Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cause of Death; Cross-Over Studies; Death, Sudden, Cardiac | 2005 |
Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cause of Death; Cross-Over Studies; Death, Sudden, Cardiac | 2005 |
Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cause of Death; Cross-Over Studies; Death, Sudden, Cardiac | 2005 |
Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cause of Death; Cross-Over Studies; Death, Sudden, Cardiac | 2005 |
Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cause of Death; Cross-Over Studies; Death, Sudden, Cardiac | 2005 |
Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cause of Death; Cross-Over Studies; Death, Sudden, Cardiac | 2005 |
Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cause of Death; Cross-Over Studies; Death, Sudden, Cardiac | 2005 |
Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cause of Death; Cross-Over Studies; Death, Sudden, Cardiac | 2005 |
Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cause of Death; Cross-Over Studies; Death, Sudden, Cardiac | 2005 |
Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cause of Death; Cross-Over Studies; Death, Sudden, Cardiac | 2005 |
Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cause of Death; Cross-Over Studies; Death, Sudden, Cardiac | 2005 |
Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cause of Death; Cross-Over Studies; Death, Sudden, Cardiac | 2005 |
Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cause of Death; Cross-Over Studies; Death, Sudden, Cardiac | 2005 |
Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cause of Death; Cross-Over Studies; Death, Sudden, Cardiac | 2005 |
Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cause of Death; Cross-Over Studies; Death, Sudden, Cardiac | 2005 |
Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cause of Death; Cross-Over Studies; Death, Sudden, Cardiac | 2005 |
Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cause of Death; Cross-Over Studies; Death, Sudden, Cardiac | 2005 |
Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cause of Death; Cross-Over Studies; Death, Sudden, Cardiac | 2005 |
Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cause of Death; Cross-Over Studies; Death, Sudden, Cardiac | 2005 |
Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cause of Death; Cross-Over Studies; Death, Sudden, Cardiac | 2005 |
Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cause of Death; Cross-Over Studies; Death, Sudden, Cardiac | 2005 |
Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cause of Death; Cross-Over Studies; Death, Sudden, Cardiac | 2005 |
Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cause of Death; Cross-Over Studies; Death, Sudden, Cardiac | 2005 |
Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cause of Death; Cross-Over Studies; Death, Sudden, Cardiac | 2005 |
Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cause of Death; Cross-Over Studies; Death, Sudden, Cardiac | 2005 |
Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cause of Death; Cross-Over Studies; Death, Sudden, Cardiac | 2005 |
Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cause of Death; Cross-Over Studies; Death, Sudden, Cardiac | 2005 |
Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cause of Death; Cross-Over Studies; Death, Sudden, Cardiac | 2005 |
Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cause of Death; Cross-Over Studies; Death, Sudden, Cardiac | 2005 |
Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cause of Death; Cross-Over Studies; Death, Sudden, Cardiac | 2005 |
Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cause of Death; Cross-Over Studies; Death, Sudden, Cardiac | 2005 |
Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cause of Death; Cross-Over Studies; Death, Sudden, Cardiac | 2005 |
Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cause of Death; Cross-Over Studies; Death, Sudden, Cardiac | 2005 |
Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cause of Death; Cross-Over Studies; Death, Sudden, Cardiac | 2005 |
Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cause of Death; Cross-Over Studies; Death, Sudden, Cardiac | 2005 |
Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cause of Death; Cross-Over Studies; Death, Sudden, Cardiac | 2005 |
Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cause of Death; Cross-Over Studies; Death, Sudden, Cardiac | 2005 |
Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cause of Death; Cross-Over Studies; Death, Sudden, Cardiac | 2005 |
Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cause of Death; Cross-Over Studies; Death, Sudden, Cardiac | 2005 |
Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cause of Death; Cross-Over Studies; Death, Sudden, Cardiac | 2005 |
Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cause of Death; Cross-Over Studies; Death, Sudden, Cardiac | 2005 |
Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cause of Death; Cross-Over Studies; Death, Sudden, Cardiac | 2005 |
Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cause of Death; Cross-Over Studies; Death, Sudden, Cardiac | 2005 |
Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cause of Death; Cross-Over Studies; Death, Sudden, Cardiac | 2005 |
Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cause of Death; Cross-Over Studies; Death, Sudden, Cardiac | 2005 |
Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cause of Death; Cross-Over Studies; Death, Sudden, Cardiac | 2005 |
Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cause of Death; Cross-Over Studies; Death, Sudden, Cardiac | 2005 |
Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cause of Death; Cross-Over Studies; Death, Sudden, Cardiac | 2005 |
Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cause of Death; Cross-Over Studies; Death, Sudden, Cardiac | 2005 |
Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cause of Death; Cross-Over Studies; Death, Sudden, Cardiac | 2005 |
Determinants of sudden cardiac death in patients with persistent atrial fibrillation in the rate control versus electrical cardioversion (RACE) study.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Calcium | 2006 |
Absence of bilateral vision loss from amiodarone: a randomized trial.
Topics: Amiodarone; Death, Sudden, Cardiac; Dose-Response Relationship, Drug; Double-Blind Method; Follow-Up | 2007 |
Risk of thromboembolism in heart failure: an analysis from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT).
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Death, Sudden, Cardiac; Defibrillator | 2007 |
The safety of amiodarone in patients with heart failure.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; | 2007 |
Outcome in African Americans and other minorities in the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT).
Topics: Amiodarone; Anti-Arrhythmia Agents; Black or African American; Cause of Death; Death, Sudden, Cardia | 2008 |
Syncope predicts the outcome of cardiomyopathy patients: analysis of the SCD-HeFT study.
Topics: Adult; Amiodarone; Anti-Arrhythmia Agents; Cardiomyopathies; Death, Sudden, Cardiac; Defibrillators, | 2008 |
Primary prevention with defibrillator therapy in women: results from the Sudden Cardiac Death in Heart Failure Trial.
Topics: Amiodarone; Anti-Arrhythmia Agents; Canada; Cohort Studies; Comorbidity; Death, Sudden, Cardiac; Def | 2008 |
Comparison of the effects of amiodarone versus metoprolol on the frequency of ventricular arrhythmias and on mortality after acute myocardial infarction. SSSD Investigators. Spanish Study on Sudden Death.
Topics: Aged; Amiodarone; Cardiac Complexes, Premature; Death, Sudden, Cardiac; Female; Humans; Male; Metopr | 1993 |
Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure.
Topics: Actuarial Analysis; Aged; Amiodarone; Arrhythmias, Cardiac; Cardiac Complexes, Premature; Death, Sud | 1995 |
Predictors of mortality in patients with sustained ventricular tachycardias or ventricular fibrillation and depressed left ventricular function: importance of beta-blockade.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Death, Sudden, Cardiac; Demography; Female; Follow-Up | 1995 |
Effect of amiodarone therapy on mortality in patients with left ventricular dysfunction and asymptomatic complex ventricular arrhythmias: Argentine Pilot Study of Sudden Death and Amiodarone (EPAMSA).
Topics: Aged; Amiodarone; Argentina; Death, Sudden, Cardiac; Female; Follow-Up Studies; Humans; Incidence; M | 1995 |
ICD versus drugs in cardiac arrest survivors: preliminary results of the Cardiac Arrest Study Hamburg.
Topics: Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Death, Sudden, Cardiac; Defibrillators, Implantable | 1993 |
[Long-term results of amiodarone therapy in patients with sustained ventricular tachycardia or ventricular fibrillation for prevention of cardiac sudden death].
Topics: Adult; Aged; Aged, 80 and over; Amiodarone; Death, Sudden, Cardiac; Female; Humans; Long-Term Care; | 1994 |
Randomised trial of low-dose amiodarone in severe congestive heart failure. Grupo de Estudio de la Sobrevida en la Insuficiencia Cardiaca en Argentina (GESICA)
Topics: Amiodarone; Death, Sudden, Cardiac; Female; Heart Failure; Humans; Male; Middle Aged; Prospective St | 1994 |
Effects of amiodarone on the circadian rhythm and power spectral changes of heart rate and QT interval: significance for the control of sudden cardiac death.
Topics: Aged; Amiodarone; Circadian Rhythm; Death, Sudden, Cardiac; Electrocardiography, Ambulatory; Heart R | 1994 |
Does amiodarone reduce sudden death and cardiac mortality after myocardial infarction? The European Myocardial Infarct Amiodarone Trial (EMIAT).
Topics: Adult; Aged; Amiodarone; Death, Sudden, Cardiac; Europe; Female; Humans; Male; Middle Aged; Myocardi | 1994 |
Implantable cardioverter defibrillator compared with antiarrhythmic drug treatment in cardiac arrest survivors (the Cardiac Arrest Study Hamburg).
Topics: Amiodarone; Anti-Arrhythmia Agents; Death, Sudden, Cardiac; Defibrillators, Implantable; Female; Hea | 1994 |
Preliminary results of the Cardiac Arrest Study Hamburg (CASH). CASH Investigators.
Topics: Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Death, Sudden, Cardiac; Defibrillators, Implantable | 1993 |
Long-term benefit of 1-year amiodarone treatment for persistent complex ventricular arrhythmias after myocardial infarction.
Topics: Amiodarone; Arrhythmias, Cardiac; Death, Sudden, Cardiac; Follow-Up Studies; Heart Ventricles; Human | 1993 |
[Long-term effect of amiodarone therapy following myocardial infarct in patients with complex ventricular arrhythmias].
Topics: Aged; Amiodarone; Arrhythmias, Cardiac; Death, Sudden, Cardiac; Female; Heart Ventricles; Humans; Ma | 1993 |
[Prediction of long-term efficacy of amiodarone for refractory ventricular tachycardia: clinical significance of electrophysiologic study and Holter monitoring].
Topics: Administration, Oral; Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Cardiomyopathy, Dilated; Deat | 1996 |
[Short-term and long-term outcome of left heart function after cardioverter defibrillator implantation].
Topics: Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Death, Sudden, Cardiac; Defibrillators, Implantable | 1996 |
Nonsustained ventricular tachycardia in severe heart failure. Independent marker of increased mortality due to sudden death. GESICA-GEMA Investigators.
Topics: Amiodarone; Analysis of Variance; Anti-Arrhythmia Agents; Cohort Studies; Confidence Intervals; Deat | 1996 |
Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT. European Myocardial Infarct Amiodarone Trial Investigators.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Death, Sudden, Cardiac; Double-Blind | 1997 |
Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT. European Myocardial Infarct Amiodarone Trial Investigators.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Death, Sudden, Cardiac; Double-Blind | 1997 |
Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT. European Myocardial Infarct Amiodarone Trial Investigators.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Death, Sudden, Cardiac; Double-Blind | 1997 |
Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT. European Myocardial Infarct Amiodarone Trial Investigators.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Death, Sudden, Cardiac; Double-Blind | 1997 |
Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT. Canadian Amiodarone Myocardial Infarction Arrhythmia Trial Investigators.
Topics: Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Death, Sud | 1997 |
Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT. Canadian Amiodarone Myocardial Infarction Arrhythmia Trial Investigators.
Topics: Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Death, Sud | 1997 |
Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT. Canadian Amiodarone Myocardial Infarction Arrhythmia Trial Investigators.
Topics: Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Death, Sud | 1997 |
Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT. Canadian Amiodarone Myocardial Infarction Arrhythmia Trial Investigators.
Topics: Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Death, Sud | 1997 |
Heart rate is a marker of amiodarone mortality reduction in severe heart failure. The GESICA-GEMA Investigators. Grupo de Estudio de la Sobrevida en la Insuficiencia Cardiaca en Argentina-Grupo de Estudios Multicéntricos en Argentina.
Topics: Amiodarone; Anti-Arrhythmia Agents; Death, Sudden, Cardiac; Female; Follow-Up Studies; Heart Failure | 1997 |
Effects of amiodarone on the circadian pattern of sudden cardiac death (Department of Veterans Affairs Congestive Heart Failure-Survival Trial of Antiarrhythmic Therapy).
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Circadian Rhythm; Death, Sudden, Cardiac; Double-Blind Met | 1997 |
Risk stratification and clinical outcome of minimally symptomatic and asymptomatic patients with nonsustained ventricular tachycardia and coronary disease: a prospective single-center study.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Confounding Factors, Epidemiologic; Coronary Disease; Deat | 1997 |
Prevalence and significance of nonsustained ventricular tachycardia in patients with premature ventricular contractions and heart failure treated with vasodilator therapy. Department of Veterans Affairs CHF STAT Investigators.
Topics: Aged; Amiodarone; Death, Sudden, Cardiac; Electrocardiography, Ambulatory; Heart Failure; Humans; Mi | 1998 |
Nonsustained ventricular tachycardia as a predictor for sudden death in patients with idiopathic dilated cardiomyopathy. The role of amiodarone treatment.
Topics: Adolescent; Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Cardiomyopathy, Dilated; Chi-Square Dis | 1999 |
Dual chamber pacing in patients with severe heart failure on beta blocker and amiodarone treatment: preliminary results of a randomised study.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Carbazoles; Cardiac Pacing, Artific | 2002 |
Electrophysiologically guided amiodarone therapy versus the implantable cardioverter-defibrillator for sustained ventricular tachyarrhythmias after myocardial infarction: results of long-term follow-up.
Topics: Amiodarone; Anti-Arrhythmia Agents; Death, Sudden, Cardiac; Defibrillators, Implantable; Disease-Fre | 2002 |
QRS duration and mortality in patients with congestive heart failure.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Bundle-Branch Block; Death, Sudden, Cardiac; Electrocardio | 2002 |
[Prospective long-term ECG study of 100 patients surviving sudden cardiac death].
Topics: Adult; Aged; Amiodarone; Death, Sudden, Cardiac; Defibrillators, Implantable; Electrocardiography, A | 1992 |
[Risk stratification and long-term therapy with amiodarone in patients with idiopathic dilated cardiomyopathy].
Topics: Adult; Aged; Amiodarone; Cardiomyopathy, Dilated; Death, Sudden, Cardiac; Electrocardiography; Femal | 1992 |
[Amiodarone and secondary prevention. The EMIAT study].
Topics: Amiodarone; Cardiac Complexes, Premature; Death, Sudden, Cardiac; Double-Blind Method; Humans; Myoca | 1991 |
Prospective, double-blind, placebo-controlled trial of low-dose amiodarone in patients with severe heart failure and asymptomatic frequent ventricular ectopy.
Topics: Adult; Aged; Amiodarone; Arrhythmias, Cardiac; Death, Sudden, Cardiac; Double-Blind Method; Feasibil | 1991 |
86 other studies available for amiodarone and Death, Sudden, Cardiac
| Article | Year |
|---|---|
Propafenone use in coronary artery disease patients undergoing atrial fibrillation ablation.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Coronary Artery Disease; Death, Sudden, Car | 2022 |
Amiodarone for the prevention of shocks and death in patients with implantable cardioverter-defibrillators: Hero or villain?
Topics: Amiodarone; Anti-Arrhythmia Agents; Death, Sudden, Cardiac; Defibrillators, Implantable; Humans; Ven | 2023 |
Natural History and Risk Stratification in Andersen-Tawil Syndrome Type 1.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Amiodarone; Andersen Syndrome; Anti-Arrhythmia Agent | 2020 |
Ventricular tachycardia converts to sinus rhythm after administration of propofol.
Topics: Amiodarone; Anesthetics, Intravenous; Anti-Arrhythmia Agents; Death, Sudden, Cardiac; Defibrillators | 2021 |
Use of Antiarrhythmic Medications in Medicare Part D Patients With an Implantable Cardioverter-Defibrillator and Ventricular Tachycardia.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Databases, | 2017 |
[Severe ventricular arrhythmias in a patient with dilated cardiomyopathy and automated implantable defibrillator (AID)].
Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cardiomyopathy, Dilated; Death, Sudden, Ca | 2017 |
A delayed diagnosis of catecholaminergic polymorphic ventricular tachycardia with a mutant of RYR2 at c.7580T>G for 6 years in a 9-year-old child.
Topics: Amiodarone; Anti-Arrhythmia Agents; Child; Death, Sudden, Cardiac; Delayed Diagnosis; Electrocardiog | 2018 |
Implantable cardioverter-defibrillators for treatment of sustained ventricular arrhythmias in patients with Chagas' heart disease: comparison with a control group treated with amiodarone alone.
Topics: Accelerated Idioventricular Rhythm; Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Chagas Cardiomy | 2014 |
Implantable Cardioverter-defibrillator Therapy for Hypertrophic Cardiomyopathy: Usefulness in Primary and Secondary Prevention.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Calcium Ch | 2015 |
Where to go in risk stratification for sudden cardiac death: Are P values enough?
Topics: Amiodarone; Arrhythmias, Cardiac; Death, Sudden, Cardiac; Electrocardiography, Ambulatory; Female; H | 2015 |
[Primary prevention of sudden cardiac death: Amiodarone is more effective than other antiarrhythmics].
Topics: Amiodarone; Anti-Arrhythmia Agents; Death, Sudden, Cardiac; Humans; Primary Prevention; Secondary Pr | 2016 |
Amiodarone for the Prevention of Sudden Cardiac Death.
Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Combined Modality Therapy; Death, Sudden, | 2016 |
[Predictive parameters of occurrence of adequate interventions in patients with implanted cardioverter-defibrillators with or without resynchronisation therapy in primary prevention of sudden cardiac death in dilated cardiomyopathy].
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cardiac Resynchronization Therapy; C | 2017 |
Defibrillation threshold testing in implantable cardioverter-defibrillators: might less be more than enough?
Topics: Amiodarone; Anti-Arrhythmia Agents; Death, Sudden, Cardiac; Defibrillators, Implantable; Differentia | 2008 |
Clinical criteria for predicting benefit of ICD/PM in post myocardial infarction patients: an AVID and CAST analysis.
Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Clinical Trials as Topic; Death, Sudden, C | 2008 |
Cost-benefit analysis of primary prevention of sudden cardiac death with an implantable cardioverter defibrillator versus amiodarone in Canada.
Topics: Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Canada; Cost-Benefit Analysis; D | 2009 |
Letter by Dardas and Aaronson regarding article, "Impact of implantable cardioverter-defibrillator, amiodarone, and placebo on the mode of death in stable patients with heart failure: analysis from the sudden cardiac death in heart failure trial".
Topics: Amiodarone; Anti-Arrhythmia Agents; Death, Sudden, Cardiac; Defibrillators, Implantable; Equipment F | 2010 |
Prognostic predictors in arrhythmogenic right ventricular cardiomyopathy: results from a 10-year registry.
Topics: Adult; Amiodarone; Anti-Arrhythmia Agents; Arrhythmogenic Right Ventricular Dysplasia; Death, Sudden | 2011 |
Letter by Ayalloore and LeLorier regarding article, "Relationship between nonsustained ventricular tachycardia after non-ST-elevation acute coronary syndrome and sudden cardiac death: observations from the Metabolic Efficiency with Ranolazine for Less Isc
Topics: Acetanilides; Acute Coronary Syndrome; Amiodarone; Anti-Arrhythmia Agents; Death, Sudden, Cardiac; E | 2011 |
Modifiable practices associated with sudden death among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Death, Sudden, Cardiac; Dialysis Sol | 2012 |
Circulating heart-type fatty acid binding protein levels predict the occurrence of appropriate shocks and cardiac death in patients with implantable cardioverter-defibrillators.
Topics: Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiomyopa | 2012 |
Effect of risk stratification on cost-effectiveness of the implantable cardioverter defibrillator.
Topics: Amiodarone; Anti-Arrhythmia Agents; Clinical Trials as Topic; Cost-Benefit Analysis; Death, Sudden, | 2002 |
Sudden death due to atrial fibrillation in hypertrophic cardiomyopathy: a predictable event in a young patient.
Topics: Adult; Amiodarone; Atrial Fibrillation; Cardiomyopathy, Hypertrophic; Death, Sudden, Cardiac; Defibr | 2003 |
A guide to device selection: cardiac resynchronization therapy alone or in combination with an implantable cardioverter defibrillator.
Topics: Amiodarone; Anti-Arrhythmia Agents; Death, Sudden, Cardiac; Defibrillators, Implantable; Equipment D | 2003 |
Clinical usefulness of electrophysiologic testing in patients with ventricular tachycardia and chronic chagasic cardiomyopathy treated with amiodarone or sotalol.
Topics: Adult; Amiodarone; Anti-Arrhythmia Agents; Brazil; Chagas Cardiomyopathy; Death, Sudden, Cardiac; Dr | 2003 |
Do we need a randomized trial of defibrillator therapy in every subset of patients with increased risk of sudden death?
Topics: Amiodarone; Anti-Arrhythmia Agents; Chagas Cardiomyopathy; Death, Sudden, Cardiac; Defibrillators, I | 2003 |
Electrical storm: case series and review of management.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Anti-Obesity Agents; B | 2003 |
Shocks from pacemaker cardioverter defibrillators increase with amiodarone in patients at high risk for sudden cardiac death.
Topics: Aged; Amiodarone; Case-Control Studies; Death, Sudden, Cardiac; Defibrillators, Implantable; Dose-Re | 2003 |
Clinical trials of prophylactic implantable defibrillator therapy in patients with nonischemic cardiomyopathy: what have we learned and what can we expect from future trials?
Topics: Adrenergic beta-Antagonists; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhythmia A | 2003 |
Different predictive values of electrophysiological testing and autonomic assessment in patients surviving a sustained arrhythmic episode.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Baroreflex; D | 2004 |
Randomized clinical trials: how long should they last?
Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cost-Benefit Analysis; Death, Sudden, Card | 2004 |
[Correction of baroreflex sensitivity impairment and efficacy of prevention of sudden arrhythmic death in patients with postinfarction left ventricular dysfunction].
Topics: Adrenergic beta-Antagonists; Adult; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti | 2004 |
Letter regarding article by Bokhari et al, "Long-term comparison of the implantable cardioverter defibrillator versus amiodarone: eleven-year follow-up of a subset of patients in the Canadian Implantable Defibrillator Study (CIDS)".
Topics: Amiodarone; Anti-Arrhythmia Agents; Canada; Cost-Benefit Analysis; Death, Sudden, Cardiac; Defibrill | 2005 |
Effect of concomitant antiarrhythmic therapy on survival in patients with implantable cardioverter defibrillators.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Combined Moda | 2005 |
[Amiodarone or ICD in patients with cardiac insufficiency. SCD-HeFT Study].
Topics: Amiodarone; Anti-Arrhythmia Agents; Cause of Death; Clinical Trials as Topic; Cross-Over Studies; De | 2006 |
Left ventricular outflow tract obstruction and sudden death risk in patients with hypertrophic cardiomyopathy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amiodarone; Cardiomyopathy, Hypertrophic; Death, Sudden, | 2006 |
Evidence that pharmacological strategies lack efficacy for the prevention of sudden death in hypertrophic cardiomyopathy.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Cardiomyop | 2007 |
Electrophysiological study and 'slow' ventricular tachycardia predict appropriate therapy: results from a single-centre implantable cardiac defibrillator follow-up.
Topics: Accelerated Idioventricular Rhythm; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Dea | 2007 |
ICD patients with elevated defibrillation threshold: clinical behavior and therapeutic alternatives.
Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Death, Sudden, Cardiac; Defibrillators, Im | 2008 |
Usefulness of Holter monitoring in predicting efficacy of amiodarone therapy for sustained ventricular tachycardia associated with coronary artery disease.
Topics: Actuarial Analysis; Amiodarone; Cardiac Complexes, Premature; Coronary Disease; Death, Sudden, Cardi | 1994 |
Is there increased sympathetic activity in patients with hypertrophic cardiomyopathy?
Topics: Adolescent; Adult; Amiodarone; Cardiomyopathy, Hypertrophic; Case-Control Studies; Circadian Rhythm; | 1995 |
Amiodarone and the heart.
Topics: Amiodarone; Atrial Fibrillation; Death, Sudden, Cardiac; Dose-Response Relationship, Drug; Heart Fai | 1995 |
Amiodarone and torsades de pointes in patients with advanced heart failure.
Topics: Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Chi-Square Distribution; Deat | 1995 |
Amiodarone: should we use it more than we do?
Topics: Amiodarone; Arrhythmias, Cardiac; Atrial Fibrillation; Cardiac Complexes, Premature; Death, Sudden, | 1993 |
Ambulatory assessment of the QT interval in patients with hypertrophic cardiomyopathy: risk stratification and effect of low dose amiodarone.
Topics: Adult; Amiodarone; Cardiomyopathy, Hypertrophic; Death, Sudden, Cardiac; Electrocardiography; Humans | 1994 |
Sudden cardiac death and the potential role of beta adrenoceptor-blocking drugs.
Topics: Adrenergic beta-Antagonists; Amiodarone; Death, Sudden, Cardiac; Humans; Myocardial Infarction | 1994 |
[Recurrent ventricular fibrillation, right bundle-branch block and persistent ST segment elevation in V1-V3: a new arrhythmia syndrome? A clinical case report].
Topics: Aged; Amiodarone; Bundle-Branch Block; Combined Modality Therapy; Death, Sudden, Cardiac; Defibrilla | 1993 |
Comparison of QT dispersion in hypertrophic cardiomyopathy between patients with and without ventricular arrhythmias and sudden death.
Topics: Adolescent; Adult; Amiodarone; Cardiomyopathy, Hypertrophic; Child; Death, Sudden, Cardiac; Electroc | 1993 |
Five-year follow-up of 589 patients treated with amiodarone.
Topics: Aged; Amiodarone; Arrhythmias, Cardiac; Death, Sudden, Cardiac; Electrophysiology; Female; Follow-Up | 1993 |
Acute fatality following pulmonary angiography in a patient on an amiodarone regimen--a case report.
Topics: Amiodarone; Angiography; Contrast Media; Death, Sudden, Cardiac; Drug Interactions; Humans; Male; Mi | 1993 |
Stratification of sudden death risk in patients receiving long-term amiodarone treatment for sustained ventricular tachycardia or ventricular fibrillation.
Topics: Actuarial Analysis; Amiodarone; Death, Sudden, Cardiac; Defibrillators, Implantable; Female; Follow- | 1993 |
Effects of a new amiodarone-like agent, SR 33589, in comparison to amiodarone, D,L-sotalol, and lignocaine, on ischemia-induced ventricular arrhythmias in anesthetized pigs.
Topics: Amiodarone; Analysis of Variance; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Benzofurans | 1995 |
Induction of ventricular fibrillation predicts sudden death in patients treated with amiodarone because of ventricular tachyarrhythmias after a myocardial infarction.
Topics: Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Cardiac Pacing, Artificial; Deat | 1996 |
Amiodarone in congestive heart failure: unravelling the GESICA and CHF-STAT differences.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Death, Sudden, Cardiac; Defibrillators, Implantable; Femal | 1996 |
Should survivors of myocardial infarction with low ejection fraction be routinely referred to arrhythmia specialists?
Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Death, Sudden, Cardiac; Defibrillators, Im | 1996 |
[Predictive factors of induction of ventricular arrhythmia under amiodarone].
Topics: Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Cardiac Pacing, Artificial; Death, Sudden, Cardiac; | 1996 |
Cost-effectiveness of implantable cardioverter defibrillators relative to amiodarone for prevention of sudden cardiac death.
Topics: Amiodarone; Anti-Arrhythmia Agents; Cost-Benefit Analysis; Death, Sudden, Cardiac; Decision Trees; D | 1997 |
Effect of amiodarone on QT dispersion in the 12-lead standard electrocardiogram and its significance for subsequent arrhythmic events.
Topics: Amiodarone; Anti-Arrhythmia Agents; Death, Sudden, Cardiac; Dose-Response Relationship, Drug; Drug A | 1997 |
Amiodarone as treatment for atrial tachycardias after surgery.
Topics: Administration, Oral; Adolescent; Adult; Amiodarone; Anti-Arrhythmia Agents; Atrial Flutter; Cathete | 1997 |
Introduction: primary prevention against sudden cardiac death.
Topics: Amiodarone; Anti-Arrhythmia Agents; Controlled Clinical Trials as Topic; Death, Sudden, Cardiac; Def | 1997 |
Why the antiarrhythmics versus implantable defibrillator (AVID) trial sets the wrong precedent.
Topics: Amiodarone; Anti-Arrhythmia Agents; Bias; Death, Sudden, Cardiac; Defibrillators, Implantable; Ethic | 1997 |
Arrhythmogenic marker for the sudden unexplained death syndrome in Thai men.
Topics: Adult; Amiodarone; Anti-Arrhythmia Agents; Asia, Southeastern; Bundle-Branch Block; Death, Sudden, C | 1997 |
Effect of amiodarone on mortality.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Death, Sudden, Cardiac; Humans; Myo | 1998 |
Right bundle-branch block and ST-segment elevation in leads V1 through V3: a marker for sudden death in patients without demonstrable structural heart disease.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Amiodarone; Anti-Arrhythmia Agents; Bundle-Branch Bl | 1998 |
[Sudden death in young persons caused by arrhythmogenic right ventricular dysplasia].
Topics: Adolescent; Amiodarone; Anti-Arrhythmia Agents; Arrhythmogenic Right Ventricular Dysplasia; Death, S | 1998 |
Hypertrophic cardiomyopathy: is there a role for amiodarone?
Topics: Adolescent; Adult; Amiodarone; Anti-Arrhythmia Agents; Cardiomyopathy, Hypertrophic; Death, Sudden, | 1998 |
Prognostic value of non-sustained ventricular tachycardia and the potential role of amiodarone treatment in hypertrophic cardiomyopathy: assessment in an unselected non-referral based patient population.
Topics: Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Cardiomyopathy, Hypertrophic; Death, Sudden, Cardia | 1998 |
Amiodarone induced epididymitis in children.
Topics: Adolescent; Adult; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Child; Death, Sudden, Ca | 1998 |
Survival after cardiac arrest or sustained ventricular tachycardia in patients with hypertrophic cardiomyopathy.
Topics: Adolescent; Adult; Amiodarone; Anti-Arrhythmia Agents; Cardiomyopathy, Hypertrophic; Child; Death, S | 1999 |
Heart failure: a diagnostic and therapeutic dilemma in elderly patients.
Topics: Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Clinical Trials as Topic; Death | 1999 |
Arrhythmogenic right ventricular dysplasia. An illustrated review highlighting developments in the diagnosis and management of this potentially fatal condition.
Topics: Adrenergic beta-Antagonists; Adult; Amiodarone; Anti-Arrhythmia Agents; Arrhythmogenic Right Ventric | 2000 |
Temporal and geographical trends in indications for implantation of cardiac defibrillators in Europe 1993-1998. Medtronic ICD System Investigators.
Topics: Amiodarone; Anti-Arrhythmia Agents; Cardiomyopathies; Coronary Disease; Death, Sudden, Cardiac; Defi | 2000 |
Are implantable cardioverter- defibrillators cost-effective?
Topics: Amiodarone; Anti-Arrhythmia Agents; Cost-Benefit Analysis; Death, Sudden, Cardiac; Defibrillators, I | 2000 |
Life-threatening arrhythmias and therapy.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Critical Care | 2000 |
[Heart failure and sudden cardiac death: pharmacological and nonpharmacological treatment possibilities from the viewpoint of the rhythmologist].
Topics: Amiodarone; Anti-Arrhythmia Agents; Bundle-Branch Block; Cardiac Pacing, Artificial; Clinical Trials | 2000 |
Potential cost-effectiveness of prophylactic use of the implantable cardioverter defibrillator or amiodarone after myocardial infarction.
Topics: Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cost-Benef | 2001 |
Summaries for patients. Cost-effectiveness of implantable defibrillators versus the drug amiodarone to prevent abnormal heart rhythms after heart attack.
Topics: Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Computer S | 2001 |
[The amiodarone-beta blockers combination could represent an alternative treatment in patients at risk for sudden death in which a benefit from implantable defibrillators has not been clearly demonstrated].
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Death, Sudden, Cardiac; Defibrillat | 2002 |
Prognostic value of heart rate variability in chronic congestive heart failure (Veterans Affairs' Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure).
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Chronic Disease; Comorbidity; Death, | 2002 |
Arrhythmia and hypertrophic cardiomyopathy.
Topics: Amiodarone; Atrial Fibrillation; Cardiomyopathy, Hypertrophic; Death, Sudden, Cardiac; Digoxin; Elec | 1992 |
Slowing of ventricular tachycardia as a possible endpoint for serial drug testing at electrophysiological study.
Topics: Amiodarone; Anti-Arrhythmia Agents; Cardiac Pacing, Artificial; Death, Sudden, Cardiac; Female; Hear | 1992 |
Cost effectiveness of the implantable cardioverter defibrillator: a preliminary analysis.
Topics: Amiodarone; Cost-Benefit Analysis; Death, Sudden, Cardiac; Defibrillators, Implantable; Electric Cou | 1992 |
Cost-effectiveness of the implantable cardioverter-defibrillator: effect of improved battery life and comparison with amiodarone therapy.
Topics: Amiodarone; Cost-Benefit Analysis; Costs and Cost Analysis; Death, Sudden, Cardiac; Decision Support | 1992 |
Long-term treatment of ventricular tachycardia with amiodarone in presence of severe left ventricular dysfunction.
Topics: Adult; Aged; Aged, 80 and over; Amiodarone; Cardiomyopathies; Coronary Disease; Death, Sudden, Cardi | 1991 |
Survival of patients with nonsustained ventricular tachycardia and impaired left ventricular function treated with low-dose amiodarone.
Topics: Aged; Amiodarone; Death, Sudden, Cardiac; Female; Heart Ventricles; Humans; Male; Middle Aged; Survi | 1991 |
Intravenous amiodarone for short-term treatment of refractory ventricular tachycardia or fibrillation.
Topics: Aged; Amiodarone; Death, Sudden, Cardiac; Drug Evaluation; Electrocardiography; Female; Humans; Infu | 1991 |